epirubicin has been researched along with paclitaxel in 561 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.18) | 18.7374 |
| 1990's | 55 (9.80) | 18.2507 |
| 2000's | 261 (46.52) | 29.6817 |
| 2010's | 210 (37.43) | 24.3611 |
| 2020's | 34 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, CP; Keller, PA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Cheng, E; Chuang, YJ; Niedzwiecki, D; Sordillo, PP; Sternberg, CN | 1 |
| Djavanmard, MP; Gnant, MF; Jakesz, R; Steger, GG | 1 |
| Sevin, BU; Untch, M | 1 |
| Catimel, G; Chazard, M; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Soler-Michel, P; Spielmann, M | 1 |
| Baldini, E; Biadi, O; Conte, PF; DaPrato, M; Gentile, A; Giannessi, PG; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Diergarten, K; duBois, A; Hecker, D; Janicke, F; Konecny, G; Kuhnle, H; Lindner, C; Lisboa, BW; Luck, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Michelotti, A; Salvadori, B; Salzano, E; Tibaldi, C | 1 |
| Holmes, FA | 1 |
| Davey, MW; Davey, RA; Marks, DC; Su, GM | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Giannessi, PG; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Bonneterre, J; Catimel, G; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Spielmann, M; Tubiana-Hulin, M | 1 |
| Diergarten, K; du Bois, A; Hecker, D; Jänicke, F; Konecny, G; Kühnle, H; Lindner, C; Lisboa, BW; Lück, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Colleoni, M; Manente, P; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G | 1 |
| Du Bois, A; Hecker, D; Köhler, G; Lisboa, B; Lück, HJ; Thomssen, C; Untch, M | 1 |
| Berruti, A; Dogliotti, L; Gorzegno, G; Tampellini, M | 1 |
| Battaglia, M; Bertolini, F; Da Prada, GA; Gibelli, N; Pavesi, L; Pedrazzoli, P; Perotti, C; Preti, P; Robustelli della Cuna, G; Salvaneschi, L; Torretta, L | 1 |
| Baldini, E; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Dell'Anna, R; Gennari, A; Gentile, A; Innocenti, F; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Diergarten, K; du Bois, A; Köhler, G; Lisboa, B; Lück, HJ; Thomssen, C; Untch, M | 2 |
| Fuechsel, G; Kettner, E; Köhler, U; Olbricht, SS; Richter, B; Ridwelski, K | 1 |
| Carmichael, J; Hutchinson, T; Jones, A | 1 |
| Dicato, M; Duhem, C; Kleiber, K; Ries, F | 1 |
| Conte, PF; Gennari, A | 1 |
| Gabriele, A; Gorga, G; Landoni, F; Lissoni, A; Mangioni, C; Sessa, C; Tumolo, S | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Bengala, C; Conte, PF; Favre, C; Greco, F; Macchia, P; Mazzoni, A; Menconi, MC; Pazzagli, I; Tibaldi, C; Vanacore, R | 1 |
| Bengala, C; Conte, PF; Gennari, A; Pazzagli, C; Salvadori, B | 1 |
| Campani, R; Delnevo, D; Ferrozzi, F; Schiavi, A | 1 |
| Cardarelli, N; Cascinu, S; Catalano, G; Giordani, P; Graziano, F; Marcellini, M; Menichetti, ET | 1 |
| Cividalli, A; Cordelli, E; Cruciani, G; Eletti, B; Livdi, E; Tirindelli Danesi, D | 1 |
| Asanuma, F; Kawamura, E; Kobayashi, H; Kubota, T; Lee, K; Suzuki, T; Yamada, T; Yamada, Y | 1 |
| Colombo, T; D'Incalci, M; Riva, A; Schüller, J; Zucchetti, M | 1 |
| Pagani, O | 1 |
| Bastert, G; Goldschmidt, H; Haas, R; Hohaus, S; Huober, J; Martin, S; Meyer, A; Schneeweiss, A; Wallwiener, D; Wittmann, G | 1 |
| Amoroso, M; Bolis, G; Parazzini, F; Pirletti, E; Polatti, A; Rabaiotti, E; Reina, S; Scarfone, G; Villa, A | 1 |
| De Bruyn, E; Highley, M; Schrijvers, D; Van Oosterom, AT; Vermorken, JB | 1 |
| Da Prada, GA; della Cuna, GR; Pedrazzoli, P; Ponchio, L; Zibera, C | 1 |
| Bianco, AR; Carlomagno, C; Casella, G; De Placido, G; De Placido, S; Ferrari, E; Fiorentino, R; Iodice, F; Lauria, R; Maffeo, A; Morabito, A; Perrone, F; Pignata, S; Ricchi, P; Tramontana, S; Varriale, E | 1 |
| Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E | 1 |
| Bauer, J; Borner, M; Buonadonna, A; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Martinelli, G; Pagani, O; Riva, A; Sessa, C; Thürlimann, B; Zampino, G; Zimatore, M | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kouroussis, C; Malamos, N; Mavroudis, D; Panagos, G; Papadouris, S; Potamianou, A; Samonis, G; Sara, E; Xydakis, E | 1 |
| Bauknecht, T; du Bois, A; Kuhn, W; Lück, HJ; Meier, W; Pfisterer, J; Quaas, J; Richter, B | 1 |
| Hada, M; Hagiwara, J; Kamiya, K; Koshizuka, K; Muto, S; Nakagomi, H; Tada, Y; Takano, K | 1 |
| Da Prada, GA; Gibelli, N; Lanza, A; Pedrazzoli, P; Perotti, C; Ponchio, L; Robustelli della Cuna, G; Salvaneschi, L; Torretta, L; Zambelli, A; Zibera, C | 1 |
| Bengala, C; Bruzzi, P; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Gennari, A; Orlandini, C; Salvadori, B | 1 |
| Freijs, A; Karlsson, MO; Sandström, M; Simonsen, LE | 1 |
| Bishop, JF; Francis, P; Ganju, V; Millward, MJ; Nawaratne, S; Rischin, D; Toner, GC; Webster, LK | 1 |
| Angiolini, C; Bergaglio, M; Del Mastro, L; Esposito, M; Garrone, O; Lunardi, G; Rosso, R; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M | 1 |
| Fattorossi, A; Greggi, S; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Salerno, G; Scambia, G | 1 |
| Apicella, A; Bianchi, U; Biglietto, M; Capasso, I; Cartenì, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Lapenta, L; Maiorino, L; Piccolo, S; Thomas, R | 1 |
| Gnant, M; Jakesz, R; Locker, GJ; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Blohmer, JU; Elling, D; Fleige, B; Grineisen, Y; Kissner, L; Lichtenegger, W; Paepke, S | 1 |
| Cortesi, E; Leone, G; Mancuso, S; Martelli, O; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Gnant, M; Jakesz, R; Janschek, E; Kandioler-Eckersberger, D; Kappel, S; Ludwig, C; Mittlböck, M; Rudas, M; Schlagbauer-Wadl, H; Steger, G; Wenzel, C | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| Bonoron-Adèle, S; Platel, D; Pouna, P; Robert, J | 1 |
| A'Hern, RP; Barton, D; Blake, P; Gore, ME; Gregory, RK; Hill, ME; Johnston, SR; Moore, J; Shephard, J | 1 |
| Aspropotamitis, A; Athanassiou, A; Dimitriadis, M; Halikia, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Avril, N; Dose, J; Graeff, H; Jänicke, F; Kuhn, W; Nährig, J; Römer, W; Sattler, D; Schelling, M; Schwaiger, M; Werner, M | 1 |
| Awasthy, BS; Gairola, M; Julka, PK; Rath, GK; Sharma, DN | 1 |
| Cree, IA; Crohns, C; Felber, M; Hepp, H; Konecny, G; Kurbacher, C; Lude, S; Pegram, M; Untch, M | 1 |
| Heimans, JJ; Hoekman, K; Postma, TJ; van Riel, JM; Vermorken, JB | 1 |
| Blijham, GH; Erdkamp, FL; Hillen, HF; Lalisang, RI; Nortier, JW; Schouten, HC; Voest, EE; Wals, J; Wils, JA | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Ceresoli, GL; Dell'Oro, S; Passoni, P; Villa, E | 1 |
| Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G | 1 |
| Carmichael, J; Howells, A; Jones, A; Lind, M; Poole, C; Stuart, N; White, J | 1 |
| Diakomanolis, E; Dimopoulos, MA; Georgoulias, N; Gika, D; Kiosses, E; Michalas, S; Moulopoulos, LA; Papadimitriou, CA; Vlahos, G; Voulgaris, Z | 1 |
| Capasso, I; Carteni, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Frezza, P; Lapenta, L; Maiorino, L; Rivellini, F; Thomas, R | 1 |
| Adachi, I | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Cosio, S; Cristofani, R; Fanucchi, A; Gadducci, A; Iacconi, P; Riccardo Genazzani, A | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Tsavaris, N; Ziras, N | 1 |
| Depisch, D; Haider, K; Kornek, G; Kwasny, W; Lang, F; Penz, M; Scheithauer, W; Ulrich-Pur, H; Valencak, J | 1 |
| Takatsuka, Y; Tominaga, T | 1 |
| Davey, M; Davey, R; Locke, V | 1 |
| Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R | 1 |
| Beyaert, R; Daniel, PT; Dörken, B; Essmann, F; Prokop, A; Schmelz, K; Schulze-Osthoff, K; Wieder, T | 1 |
| Bastert, G; Egerer, G; Goerner, R; Grischke, EM; Haas, R; Hensel, M; Ho, AD; Hohaus, S; Khbeis, T; Schneeweiss, A; Solomayer, E | 1 |
| Boccardo, F; Foglia, G; Marenghi, C; Miglietta, L; Nizzo, R; Ragni, N | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Bafaloukos, D; Briassoulis, E; Dimopoulos, AM; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Keramopoulos, A; Kosmidis, P; Papadimitriou, C; Pavlidis, N; Razis, E; Samantas, E | 1 |
| Bertuzzi, A; Capri, G; Cresta, S; Giani, A; Gianni, L; Grasselli, G; Locatelli, A; Materazzo, C; Perotti, A; Spreafico, C; Tarenzi, E; Valagussa, P; Viganò, L | 1 |
| Abela, K; Aravantinos, G; Bafaloukos, D; Briassoulis, E; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, E; Kalofonos, HP; Kosmidis, P; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pavlidis, N; Razis, E; Skarlos, D | 1 |
| Milla, L; Milla-Santos, A; Rallo, L; Solano, V | 1 |
| Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, AM; Ekonomopoulos, T; Fountzilas, G; Kalofonos, H; Nicolaides, C; Papadimitriou, C; Pavlidis, N; Skarlos, D; Stathopoulos, G | 1 |
| Pagani, O; Sessa, C | 1 |
| Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Paladini, U; Perillo, A; Pierelli, L; Salerno, MG; Scambia, G; Serafini, R | 1 |
| Dettke, M; Greinix, HT; Höcker, P; Kalhs, P; Kührer, I; Worel, N | 1 |
| Conte, P; Donati, S; Gennari, A; Landucci, E; Salvadori, B | 1 |
| Baldini, E; Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Trudeau, ME | 1 |
| Bojko, P; Borquez, D; Kasimir-Bauer, S; Mayer, S; Neumann, R; Seeber, S | 1 |
| Fountzilas, G; Razis, ED | 1 |
| Bernardo, G; Brugnatelli, S; Danova, M; Fava, S; Giardina, G; Giordano, M; Grasso, D; Montanari, G; Pedrotti, C; Poli, MA; Pugliese, P; Riccardi, A; Rinaldi, E; Tinelli, C; Trotti, G | 1 |
| Delozier, T; Fumoleau, P; Guastalla, JP; Kerbrat, P; Roché, H; Viens, P | 1 |
| Beijnen, JH; Hoekman, K; Huijskes, RV; Nannan Panday, VR; Rosing, H; Van den Brande, J; Verheijen, RH; Vermorken, JB | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Barats, JC; Blohmer, J; Du Bois, A; Goupil, A; Kuhn, W; Lück, HJ; Meier, W; Möbus, V; Mousseau, M; Pfisterer, J; Richter, B; Schröder, W; Weber, B | 1 |
| Pagani, O; Trudeau, M | 1 |
| Beryt, M; Felber, M; Hepp, H; Kahlert, S; Konecny, G; Langer, E; Lude, S; Pegram, M; Slamon, D; Untch, M | 1 |
| Bergaglio, M; Cognetti, F; Del Mastro, L; Donati, S; Frevola, L; Lionetto, R; Lunardi, G; Michelotti, A; Papaldo, P; Rosso, R; Sguotti, C; Venturini, M | 1 |
| Aloe, A; Carlini, P; Cognetti, F; De Marco, S; Fabi, A; Magnani, E; Nardi, M; Pacetti, U; Ruggeri, EM | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Baselga, J | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Carta, G; De Filippis, S; Rea, S; Recchia, F; Rosselli, M; Saggio, G | 1 |
| Ishitobi, M; Kikkawa, N; Shin, E | 1 |
| Honda, S; Kawaguchi, Y; Kimura, A; Kunieda, K; Matsui, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H | 1 |
| Kawano, R; Kuroki, S; Matsuo, K; Nagata, S; Ogawa, T; Onzuka, T; Shinohara, M; Sumitomo, K; Suzuki, H; Yamanaka, N; Yoshida, J | 1 |
| Gao, JS; Kuang, ZJ; Liu, ZC; Qian, CN; Zeng, YX; Zhang, XS; Zhu, XF | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 1 |
| Kaneko, M; Oguchi, S; Saida, T; Uhara, H | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Bighin, C; Del, ML; Esposito, M; Lunardi, G; Schettini, G; Tolino, G; Vannozzi, MO; Venturini, M | 1 |
| Haegele, P; Lehmann, S; Moyses, B; Petit, T; Rodier, JF; Schraub, S; Velten, M | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Labonia, V; Landi, G; Mastro, AA; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Inaji, H; Kobayashi, H; Motomura, K; Noguchi, S; Taguchi, T; Takamura, Y | 1 |
| D'Agostino, G; Distefano, M; Ferrandina, G; Greggi, S; Mancuso, S; Poerio, A; Salerno, M; Scambia, G | 1 |
| Conte, PF; Gennari, A; Landucci, E; Orlandini, C | 1 |
| Davis, JA; Kaye, SB; O'Neill, VJ; Paul, J; Reed, NS; Vasey, PA | 1 |
| Baldini, E; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Fogli, S; Gennari, A; Innocenti, F; Salvadori, B | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Zielinski, CC | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A | 1 |
| Chiu, HC; Chu, CY; Yang, CH | 1 |
| Cao, Y; Liu, H; Liu, P; Qiao, X; Tong, F; Yang, D; Zhang, J; Zhou, B | 2 |
| Budman, DR; Calabro, A | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Alessandroni, P; Catalano, G; Catalano, V; Fedeli, A; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Testa, E | 1 |
| Ashley, DM; Baum, CM; Caruso, DA; Koina, C; Radcliff, FJ; Riordan, MJ; Roberts, AW; Tang, ML; Woulfe, SL | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Ackland, SP; Clarke, S; Garg, MB; Millward, MJ; Rischin, D; Smith, J; Toner, GC; Zalcberg, J | 1 |
| Budman, DR | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Baranzelli, MC; Barnouin, L; Bay, JO; Bui, NB; Chevreau, C; Cupissol, D; Eymard, JC; Lortholary, A; Mita, M; Pivot, X; Savary, J; Thyss, A | 1 |
| Abali, H; Celik, I | 1 |
| Antila, K; Ekholm, E; Korpela, J; Salminen, E; Syvänen, K; Varjo, P; Varpula, M | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Chang, HK; Chen, SC; Cheung, YC; Hsueh, S; Lin, YC; See, LC; Su, MY; Tsai, CS | 1 |
| Filipits, M; Jakesz, R; Pirker, R; Pohl, G; Rudas, M; Steger, GG; Stranzl, T; Taucher, S | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Da Prada, G; Fagnoni, FF; Fregoni, V; Gibelli, N; Lozza, L; Oliviero, B; Pavesi, L; Perotti, C; Ponchio, L; Robustelli della Cuna, G; Zambelli, A; Zibera, C | 1 |
| Brinkbäumer, K; Hahn, K; Kessler, M; Linke, R; Sommer, H; Tiling, R; Untch, M | 1 |
| Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC | 1 |
| Assouline, D; Bachelot, T; Dramais, D; Guastalla, JP; Levy, E; Pujade-Lauraine, E; Ray-Coquard, I; Tigaud, JD; Vincent, P | 1 |
| Alessandrino, PE; Bertolini, A; Collovà, E; Danova, M; Ferrari, S; Porta, C; Riccardi, A; Rovati, B | 1 |
| Heinemann, V | 1 |
| Bauduceau, O; Bernard, O; Ceccaldi, B; Dourhte, LM; Hervé, R; Le Moulec, S | 1 |
| Delorme, S; Fink, C; Junkermann, H; Klein, SK; Lüdemann, HP; Sinn, HP; Wasser, K; Zuna, I | 1 |
| Benedetti Panici, P; Borsellino, N; Citarrella, P; Di Marco, P; Fallica, G; Gebbia, N; Gebbia, V; Tirrito, ML; Valenza, R; Valerio, MR | 1 |
| Archibald, H; Hutcheon, A; Macduff, C; Mackenzie, T; Melville, L | 1 |
| Carnino, F; Conte, PF; Cosio, S; Fanucchi, A; Gadducci, A; Lionetto, R; Pastorino, S; Romanini, A; Tanganelli, L | 1 |
| Baioni, M; Ballardini, M; De Giorgi, U; Ferrari, E; Marangolo, M; Minzi, MR; Rosti, G; Zaniboni, A; Zornetta, L | 1 |
| Nabholtz, JM | 1 |
| Kawaguchi, Y; Saji, S; Sugiyama, Y | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Breitbach, P; Eggemann, H; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G; Schlosser, H | 1 |
| Bruzzi, P; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B | 1 |
| Cao, Y; Liu, H; Liu, P; Qiao, X; Tong, F; Wang, S; Yang, D; Zhang, J; Zhou, B | 1 |
| Cosio, S; Cristofani, R; Fanucchi, A; Gadducci, A; Genazzani, AR; Negri, S | 1 |
| Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Buda, A; Colombo, N; Conte, PF; Floriani, I; Fossati, R; Mangioni, C; Ravaioli, A; Rossi, R; Torri, V | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Bonneterre, J; Catimel, G; Tubiana-Hulin, M | 1 |
| Jänicke, F; Köhler, G; Löning, T; Lück, HJ; Möbus, V; Müller, V; Pantel, K; Sattler, D; Thomssen, C; von Minckwitz, G; Wilczak, W; Witzel, I | 1 |
| Bengala, C; Campani, D; Collecchi, P; Conte, PF; Donati, S; Gennari, A; Guarneri, V; Maur, M; Orlandini, C | 1 |
| Dandekar, S; du Bois, A; Eidtmann, H; Jänicke, F; Konecny, GE; Kuhn, W; Lück, HJ; Möbus, V; Olbricht, S; Pauletti, G; Pegram, MD; Ramos, L; Slamon, DJ; Steinfeld, D; Thomssen, C; Untch, M; von Minckwitz, G; Wang, HJ | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Costantini, M; Giannessi, P; Guarneri, V; Mammoliti, S; Moyano, A; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Currie, VE; D'Andrea, GM; Dang, CT; Dickler, MN; Fornier, M; Hudis, CA; Hurria, A; Lake, D; Moynahan, ME; Norton, L; Panageas, KS; Robson, ME; Seidman, AD; Theodoulou, M | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Kosmidis, P; Makrantonakis, P; Maniadakis, N; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pectasides, D; Razis, E; Siafaka, V; Skarlos, D; Tsavdaridis, D | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Enomoto, T; Fujita, M; Murata, Y; Nakashima, R | 1 |
| Cui, HJ; Li, Y; Tan, HY; Wu, XQ | 1 |
| Huober, J; Mueck, AO; Seeger, H; Wallwiener, D | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Palmieri, FM; Perez, EA; Tack, DK | 1 |
| Bartoletti, R; Cipriani, G; Della Melina, A; Di Cello, V; Dominici, A; Fulignati, C; Maleci, D; Neri, B; Nicita, G; Ponchietti, R; Raugei, A; Turrini, M; Villari, D | 1 |
| Abumiya, K; Kamachi, H; Kamiyama, N; Kamiyama, T; Khor, LW; Kobayashi, H; Kurauchi, N; Matsushita, M; Nakagawa, T; Nakajima, H; Nakanishi, K; Taguchi, K; Takahashi, H; Takahashi, M; Todo, S; Tsukahara, M; Watanabe, K | 1 |
| Biron, P; Bui, B; Caty, A; Culine, S; Curé, H; De Revel, T; Delva, R; Droz, JP; Duclos, B; Fizazi, K; Gligorov, J; Gomez, F; Gravis, G; Guillemaut, S; Lotz, JP; Peny, J; Provent, S; Ségura, C; Théodore, C; Viens, P | 1 |
| Poole, C | 1 |
| Beslija, S; Brodowicz, T; Cervek, J; Chernozemsky, I; Ghilezan, N; Grgic, M; Inbar, M; Kahan, Z; Khamtsov, D; Mrsic-Krmpotic, Z; Pawlega, J; Soldatenkova, V; Spanik, S; Szanto, J; Tzekova, V; Vrbanec, D; Wagnerova, M; Welnicka-Jaskiewicz, M; Wiltschke, C; Zielinski, C | 1 |
| Arun, BK; Berry, D; Booser, DJ; Buchholz, TA; Buzdar, AU; Cristofanilli, M; Ewer, MS; Francis, D; Frye, DK; Giordano, SH; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Sahin, AA; Singletary, SE; Smith, TL; Theriault, RL; Thomas, ES | 1 |
| Abrial, C; Amat, S; Chollet, P; Delva, R; Fleury, J; Gamelin, E; Leduc, B; Penault-Llorca, F; Sillet-Bach, I; Van Praagh, I | 1 |
| Athanassiou, E; Bai, M; Catodritis, N; Daniilidis, J; Fountzilas, G; Kalogera-Fountzila, A; Karanikiotis, C; Makatsoris, T; Misailidou, D; Nicolaou, A; Papakostas, P; Papamichael, D; Plataniotis, G; Samantas, E; Tolis, C; Tsekeris, P; Zamboglou, N | 1 |
| Havsteen, H; Lindegaard, JC; Mogensen, O; Nielsen, OS; Søgaard, CH | 1 |
| Arsovski, O; Debourdeau, P; Gligorov, J; Lotz, JP | 1 |
| Arun, B; Ayers, M; Buchholz, TA; Gold, DL; Green, M; Hess, KR; Hortobagyi, GN; Kuerer, H; Pusztai, L; Rajan, R; Ross, JS; Rouzier, R; Stec, J; Symmans, WF; Wagner, P; Zhang, P | 1 |
| Chiriatti, A; Latorre, A; Lorusso, V; Mangia, A; Paradiso, A; Schittulli, F; Tommasi, S; Zito, A | 1 |
| Chang, HK; Chen, MF; Chen, SC; Cheung, YC; Hsueh, S; Leung, WM; Lin, YC; Tsai, CS | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Romano, G; Rubulotta, MR; Thomas, R | 1 |
| Abali, H; Altundag, K; Atahan, IL; Baltali, E; Engin, H; Erman, M; Guler, N; Karaoglu, A; Onat, D; Ozisik, Y; Sayek, I; Tekuzman, G | 1 |
| He, PQ; Li, YF; Liu, GY; Shen, ZZ; Sheng, Y; Shi, JY; Su, FX; Yang, MT; Zou, Q | 1 |
| Cao, YM; Liu, HJ; Liu, P; Qiao, XM; Tong, FZ; Yang, DQ; Zhou, B | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L | 1 |
| Brunetti, C; Carreca, I; Comella, G; Comella, P; D'Aiuto, M; D'Aniello, R; DeCataldis, G; Frasci, G; Giordano, R; Muci, D; Palmeri, S; Russo, A | 1 |
| Chen, MC; Cheng, AL; Hsu, CH; Whang-Peng, J; Yang, CH; Yang, PC; Yeh, KH; Yu, YC | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Ciglar, S; Kukura, V; Radić, V | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Polychronis, A; Razis, E; Siafaka, V; Skarlos, D; Timotheadou, E; Tsavdaridis, D | 1 |
| Alamanis, C; Bougas, D; Dimitrakopoulos, A; Giannopoulos, A; Kopterides, P; Kopteridis, P; Kosmas, C; Mitropoulos, D; Skopelitis, H; Stravodimos, K; Tsavaris, N | 1 |
| Nakahara, K; Ogino, T; Osanai, T; Tsuchiya, T | 1 |
| de Azambuja, E; de Castro, G; Demonty, G; Puglisi, F | 1 |
| Saito, T; Takahashi, K; Tokunaga, Y | 1 |
| Liu, HJ; Qiao, XM; Tong, FZ; Wang, S; Yang, DQ; Zhang, JQ | 1 |
| Heinemann, V; Kahlert, S; Kolb, HJ; Lindhofer, H; Menzel, H; Salat, C; Stemmler, HJ | 1 |
| Ahluwalia, MS; Daw, HA | 1 |
| Gupta, S | 1 |
| Cameron, DA; Carmichael, J; Howell, A; Jones, AL; Langley, RE; Parmar, M; Qian, W; Uscinska, B | 1 |
| Chen, B; Chen, JZ; Cui, F; Huang, YX; Luo, RC | 1 |
| Blohmer, JU; Breitbach, GP; Budner, M; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Lichtenegger, W; Morack, G | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Limeres González, MA; Pavcovich Ruiz, M | 1 |
| Hiramatsu, Y; Hongo, A; Kodama, J; Nakamura, K; Ojima, Y; Seki, N | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Barats, JC; Costa, S; du Bois, A; Goupil, A; Kimmig, R; Kuhn, W; Lueck, HJ; Meier, W; Olbricht, S; Orfeuvre, H; Pfisterer, J; Pujade-Lauraine, E; Richter, B; Rochon, J; Schroeder, W; Wagner, U; Weber, B | 1 |
| Aravantinos, G; Dimopoulos, MA; Economopoulos, T; Efstathiou, H; Farmakis, D; Fountzilas, G; Kalofonos, C; Pavlidis, N; Pectasides, D; Skarlos, D | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Iwamoto, E; Kinosita, T; Takasugi, M; Yamaguchi, J | 1 |
| Blohmer, JU; Breitbach, GP; Budner, M; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G | 1 |
| Baldini, E; Conte, PF; Del Freo, A; Fabbri, A; Falcone, A; Innocenti, F; Pennucci, MC; Prochilo, T; Russo, F; Tibaldi, C | 1 |
| De Giorgi, U; Emiliani, E; Frassineti, L; Giannini, M; Giovannini, N; Kopf, B; Marangolo, M; Palazzi, S; Rosti, G; Zumaglini, F | 1 |
| Ben Yosef, R; Sarid, D; Shalmon, A; Sperber, F; Weinstein, Y; Yaal-Hahoshen, N | 1 |
| Asukai, K; Hirahara, F; Miyagi, E; Miyamatsu, A; Nakayama, H; Nakazawa, T; Numazaki, R; Okamoto, N; Onose, R; Sugiura, K | 1 |
| Ayala, R; Cortés-Funes, H; Gamarra, S; Gilsanz, F; Guzman, C; Hitt, R; Hornedo, J; Jimeno, A; López, JM; Quintela-Fandino, M | 1 |
| Battelli, N; Braconi, C; Cascinu, S; Cobelli, S; Dinota, A; Giacomini, G; Giorgi, F; Manzione, L; Massacesi, C; Morale, D; Pilone, A; Scanni, A; Sturba, F; Tummarello, D | 1 |
| Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W | 1 |
| Amadori, D; Bruzzi, P; Conte, PF; De Lena, M; Gennari, A; Lorusso, V; Manzione, L; Nanni, O | 1 |
| Bafaloukos, D; Bourli, A; Christodoulou, C; Dafni, U; Fillipidis, T; Fountzilas, G; Gogas, H; Kafiri, G; Karagianni, E; Kyriakou, V; Malamou-Mitsi, V; Markaki, S; Papadopoulos, S; Papakostas, P; Papaspyrou, I; Pavlakis, K; Scopa, C; Sotiropoulou, M; Toliou, T; Tzaida, O; Vlachodimitropoulos, D | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Iodice, G; Rubulotta, MR; Thomas, R | 1 |
| Buyse, M; Decoster, G; Fabre-Guillevin, E; Jouhaud, A; Liénard, JL; Piedbois, P; Quinaux, E | 1 |
| Karakuzu, A; Koc, M; Ozdemir, S | 1 |
| Gianni, L; Menna, P; Minotti, G; Salvatorelli, E | 1 |
| Bria, E; Calabretta, F; Carpino, A; Cognetti, F; Cuppone, F; Ferretti, G; Nisticò, C; Sperduti, I; Terzoli, E; Toglia, G; Tomao, S; Vitelli, G | 1 |
| Atienza, M; Bromberg, J; D'Andrea, G; Fornier, MN; Hudis, C; Lake, D; Norton, L; Panageas, KS; Robson, M; Seidman, AD; Van Poznak, C | 1 |
| Broglio, KR; Buchholz, TA; Buzdar, AU; Esteva, F; Ewer, MS; Francis, D; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Sahin, AA; Singletary, SE; Symmans, WF; Theriault, RL; Valero, V | 1 |
| Suzuki, M | 1 |
| Bailey, AR; Liew, TV; Wheeler, DW | 1 |
| Ben-Yosef, R; Grinberg, Y; Kahan, P; Kovner, F; Maimon, N; Marmor, S; Ron, IG; Sarid, D; Sperber, F; Stadler, Y; Weinstein, J; Yaal-Hahoshen, N | 1 |
| Fuhr, U; Hempel, G; Hunz, M; Jaehde, U; Jetter, A; Kurbacher, C; Pantke, E; Tuscher, M; Untch, M; Warm, M | 1 |
| Choi, HY; Kang, WK; Kim, WS; Lee, HM; Lim, HY; Park, BB; Park, K; Uhm, JE | 1 |
| Ozalpan, A; Ozcan Arican, G | 1 |
| Fujiwara, Y; Ono, M | 1 |
| Broglio, K; Buzdar, AU; Dawood, S; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Kau, SW; Peintinger, F; Symmans, WF | 1 |
| Andreetta, C; Banna, G; Battelli, N; Berardi, R; Bisagni, G; Boni, C; Bottini, A; Conte, P; Cresti, N; Di Blasio, B; Ficarra, G; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Maiorana, A; Michelotti, A; Piacentini, F; Puglisi, F; Santoro, A | 1 |
| Argnani, M; Ciucci, G; De Giorgi, U; Kopf, B; Marangolo, M; Minzi, C; Rosti, G | 1 |
| Colombo, N; Landoni, F; Maggioni, A; Parma, G; Peiretti, M; Sideri, M; Zanagnolo, V | 1 |
| Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E | 1 |
| Fukuda, T; Kawahara, M; Kikuchi, S; Kodama, H; Suzuki, H; Watanabe, T | 1 |
| Akiyama, F; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Miki, Y | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Balduzzi, A; Bottiglieri, L; Colleoni, M; Ghisini, R; Giovanardi, F; Goldhirsch, A; Luini, A; Orlando, L; Rocca, A; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Altundag, K; Buzdar, AU; Esteva, FJ; Hortobagyi, GN; Lin, F; Mejia, JA; Pusztai, L; Symmans, WF; Valero, V; Wang, J; Yan, K | 1 |
| Alamani, M; Arapantoni-Dadioti, P; Aravantinos, G; Briasoulis, E; Dafni, U; Fountzilas, G; Gogas, H; Kalofonos, HP; Kastritis, E; Kostopoulos, I; Kyriakou, V; Kyroudi, A; Malamou-Mitsi, V; Papaspyrou, I; Pectasides, D; Skopa, C; Tzaida, O | 1 |
| Colombo, N; Fossati, R; Fruscio, R; Garbi, A; Ieda', N; Lissoni, AA; Mangioni, C; Torri, V | 1 |
| Aravantinos, G; Bafaloukos, D; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Papadimitriou, CA | 1 |
| Li, HZ; Wu, ZY; Yi, TB | 1 |
| Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S | 1 |
| Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F | 1 |
| Aravantinos, G; Bamias, A; Fountzilas, G; Papadimitriou, CA; Papakostas, P; Timotheadou, E | 1 |
| Chu, SC; Kao, RH; Li, CC; Wang, TF; Yao, CY | 1 |
| Gao, J; He, Z; Li, X; Li, Y; Liu, M; Tang, H; Wang, Q; Zheng, J | 1 |
| Ansari, R; Geyer, CE; Hamm, JT; Kardinal, CG; Kim, W; Lembersky, BC; Paik, S; Rastogi, P; Raymond, JM; Robidoux, A; Shalaby, IA; Song, YK; Tseng, GC; Wilson, JW; Wolmark, N | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF | 1 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Harano, M; Higaki, K; Kagemoto, M; Kin, R; Masumura, K; Matsuura, H; Ohtani, S; Takada, S; Urashima, M | 1 |
| Anan, K; Hirose, N; Mitsuyama, S; Ogawa, S; Saimura, M; Shimada, K; Tamaki, N; Tamura, K; Tanaka, M; Tomisaki, S | 1 |
| Bonazzi, C; Chiari, S; Maneo, A; Mangioni, C | 1 |
| Chung, HH; Kang, SB; Kim, JW; Kim, K; Park, NH; Song, YS | 1 |
| D'Andrea, G; Dang, C; Dickler, M; Fornier, M; George, R; Gilewski, T; Hudis, CA; Hurria, A; Lake, D; Mills, N; Moynahan, ME; Norton, L; Panageas, KS; Robson, M; Smith, K; Sugarman, S; Troso-Sandoval, T | 1 |
| Agostara, B; Belfiglio, M; Bertetto, O; Bruzzi, P; Cascinu, S; Cognetti, F; Conte, P; Crinó, L; D'Amico, R; Di Leo, A; Frassoldati, A; Guarneri, V; Molino, A; Pronzato, P | 1 |
| Akashi-Tanaka, S; Ando, M; Doihara, H; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Miyakawa, K; Seki, K; Shien, T; Shimizu, C; Taira, N | 1 |
| Cecchetto, M; Guo, B; Hembruff, SL; Laberge, ML; Parissenti, AM; Veitch, Z; Villeneuve, DJ | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Izzo, F; Nisticò, C; Sperduti, I; Terzoli, E; Tropea, F; Vaccaro, V | 1 |
| Dick, M; Harbeck, N; Hoopmann, M; Kates, R; Mallmann, P; Thomas, A; Warm, M | 1 |
| Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Petrillo, A; Rinaldo, M; Siani, C | 1 |
| Hirai, Y; Kiyoi, M; Miyasaka, M; Naito, K; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Shimizu, Y; Tamaki, T; Yoshimasu, T | 1 |
| Hoskins, PJ | 1 |
| Albert, US; Bauerfeind, I; Harbeck, N; Hinke, A; Jänicke, F; Kahlert, S; Konecny, GE; Kreienberg, R; Kuhn, W; Lebeau, A; Lück, HJ; Möbus, V; Muck, BR; Petry, KU; Schneeweiss, A; Thomssen, C; Untch, M; von Koch, F; Wallwiener, D; Werner, C | 1 |
| Asaga, T; Chishima, T; Doi, T; Hamaguchi, Y; Ichikawa, Y; Inaba, M; Ishikawa, T; Kasahara, A; Katayama, K; Kito, A; Matsumoto, C; Momiyama, N; Morita, S; Narui, K; Ohta, I; Shimada, H; Shimizu, D; Shimizu, S; Suda, T; Tanabe, M; Yamaguchi, N; Yoshimoto, M | 1 |
| Boström, PJ; Laato, M; Laihia, JK; Leino, L; Pylkkänen, L | 1 |
| Borovskaya, TG; Gol'dberg, VE; Pachomova, AV; Perova, AV; Poluektova, ME | 1 |
| Kim, SJ; Morimoto, K; Noguchi, S; Shimazu, K; Taguchi, T; Tamaki, Y; Tanei, T; Tanji, Y | 1 |
| Fischer, T; Harbeck, N; Kates, R; Thomas, A; Warm, M | 1 |
| Fu, JF; Hong, ZW; Wang, B | 1 |
| Kim, SJ; Noguchi, S; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Kaide, A; Kodama, K; Matsuoka, J; Ootawa, Y; Ootsuka, N; Watanabe, N | 1 |
| Blaskó, G; Nagy, Z; Turcsik, V | 1 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Beal, K; Damast, S; Elkin, E; Fornier, MN; Ho, AY; Ishill, N; McCormick, B; Montgomery, L | 1 |
| Albain, KS; Bramwell, V; Burnell, M; Chalchal, H; Chapman, JA; Gelmon, K; Levine, MN; O'Brien, P; Perez, EA; Pritchard, K; Rugo, H; Shepherd, LE; Vandenberg, T; Walley, B | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Hong, SW; Jeong, H; Jeong, J; Jung, W; Kim, KH; Koo, JS; Lee, HD; Shin, E | 1 |
| Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR | 1 |
| Ishiguro, K; Nishimura, M; Suda, T; Uchida, N | 1 |
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Su, XD; Tao, LY; Wang, FP; Yan, YY; Zhang, X | 1 |
| Aoyagi, H; Hamada, S; Kaneko, J; Katsuta, E; Maejima, S; Makinose, T; Okubo, K; Saguchi, M; Sato, T; Sekine, T; Someno, Y; Sugihara, K | 1 |
| Abad, M; Alba, E; Batista, N; Caballero, R; Calvo, L; Crespo, C; Cubedo, R; de Alava, E; Domínguez, S; Florián, J; García, MJ; Godes, M; Llorca, C; Martín, M; Méndez, M; Murias, A; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Santaballa, A | 1 |
| Hama, Y; Nakagawa, K | 1 |
| Buzdar, AU; Desai, AM; Fehrenbacher, L; Fourchotte, V; Geyer, CE; Jacobs, S; Mamounas, EP; Pajon, ER; Quinaux, E; Rastogi, P; Robidoux, A; Shalaby, IA; Wolmark, N; Younan, RJ | 1 |
| Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H | 1 |
| Arslan, C; Kilickap, S | 1 |
| Domoto, K; Fujibayashi, M; Hirano, A; Kamimura, M; Kim, N; Kimura, K; Kinoshita, J; Ogawa, K; Shimizu, T; Watanabe, O | 1 |
| Kostova, I; Stancheva, T; Zaprjanova, P | 1 |
| Atkins, CD | 1 |
| Bermingham, S; McMahon, GP; O'Connor, R; Regan, F | 1 |
| du Bois, A; Harbeck, N; Hinke, A; Huober, J; Jackisch, C; Konecny, GE; Kreienberg, R; Kuhn, W; Kurbacher, C; Lueck, HJ; Moebus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Fukatsu, K; Iwaya, K; Moriya, T; Osaki, A; Ueda, S; Yamamoto, J | 1 |
| Agostara, B; Amadori, D; Boccardo, F; Catalano, G; Faedi, M; Farris, A; Gambi, A; Guglielmini, P; Rubagotti, A; Sismondi, P | 1 |
| Egawa-Takata, T; Enomoto, T; Fujita, M; Kimura, T; Matsuzaki, S; Miyake, T; Miyatake, T; Ueda, Y; Yokoyama, T; Yoshino, K | 1 |
| Inaji, H; Masuda, N; Morimoto, T; Motomura, K; Nakano, Y; Nakayama, T; Noguchi, S; Nomura, T; Shimazu, K; Taguchi, T; Takatsuka, Y; Tsukamoto, F; Wakita, K; Yamamoto, H; Yoneda, K | 1 |
| Burris, HA; Daniel, B; Hainsworth, JD; Inhorn, R; Lane, CM; Naot, Y; Vazquez, ER; Yardley, DA; Zubkus, J | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 2 |
| Borowicz, H; Glados, M; Heilmann, V; Hinke, A; Jackisch, C; Lehnert, A; Möbus, V; Müller, V; Schmidt, M; Thomssen, C | 1 |
| Amant, F; de Bruijn, E; de Hoon, J; Heyns, L; Van Bree, R; Van Calsteren, K; Verbesselt, R | 1 |
| Amant, F; Chai, D; de Bruijn, E; de Hoon, J; Delforge, M; Halaska, M; Heyns, L; Noens, L; Ottevanger, N; Renard, V; Rob, L; Van Bree, R; Van Calsteren, K; Verbesselt, R; Witteveen, E | 1 |
| Becherer, A; De Vries, A; Drexel, H; Gasser, K; Gruber-Moesenbacher, U; Lang, A; Muendlein, A; Schuster, A; Winder, T | 1 |
| Conrad, B; Forstbauer, H; Koehne, CH; Kremers, S; Linder, M; Loibl, S; Moebus, V; Mueller, V; Nekljudova, V; von Minckwitz, G | 1 |
| Song, ST | 1 |
| Fujibayashi, M; Hirano, A; Kamimura, M; Kim, N; Kimura, K; Kinoshita, J; Ogawa, K; Ogura, K; Shimizu, T; Watanabe, O | 1 |
| Hudis, CA; Morris, PG | 1 |
| Bordin, F; De Marco, F; Di Nicola, S; Lanzetta, G; Rozzi, A; Salerno, M | 1 |
| Cui, L; Huang, XE; Jiang, Y; Tang, JH; Xiang, J; Yan, PW | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Naoi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanei, T; Tominaga, N; Tsunashima, R | 1 |
| Bando, H; Iwata, H; Kashiwaba, M; Mizuno, T; Murakami, S; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Yamamoto, Y | 1 |
| Beckmann, MW; Conrad, U; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Konecny, GE; Kurzeder, C; Lebeau, A; Lenhard, M; Liedtke, B; Loibl, S; Lück, HJ; Müller, V; Nekljudova, V; Salat, C; Schmidt, M; Stickeler, E; Untch, M; Urbaczyk, H; von Minckwitz, G | 1 |
| Conrad, U; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Konecny, GE; Kurzeder, C; Lebeau, A; Lenhard, M; Liedtke, B; Loibl, S; Lück, HJ; Müller, V; Nekljudova, V; Salat, C; Schmidt, M; Schuster, T; Stickeler, E; Untch, M; Urbaczyk, H; von Koch, F; von Minckwitz, G | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Baba, Y; Iwamoto, T; Kim, SJ; Kishi, K; Nakamura, Y; Nakayama, T; Naoi, Y; Noguchi, S; Oshima, K; Shimazu, K; Tamaki, Y | 1 |
| Athanassiou, H; Bobos, M; Ciuleanu, E; Ciuleanu, T; Dionysopoulos, D; Eleftheraki, AG; Fountzilas, G; Kalogera-Fountzila, A; Karayannopoulou, G; Markou, K; Misailidou, D; Nikolaou, A; Resiga, L; Samantas, E; Skarlos, D; Zaramboukas, T | 1 |
| Aas, T; Anker, G; Chrisanthar, R; Fjösne, HE; Knappskog, S; Lillehaug, JR; Lundgren, S; Løkkevik, E; Lønning, PE; Mjaaland, I; Nysted, A; Ostenstad, B; Risberg, T; Schlichting, E; Skjønsberg, G | 1 |
| Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P | 1 |
| Blijham, GH; Erdkamp, FL; Knibbeler-van Rossum, CT; Lalisang, RI; Loosveld, OJ; Nortier, JW; Rodenburg, CJ; Schouten, HC; Slee, PH; Smals, AE; Tjan-Heijnen, VC; van Bochove, A; Voest, EE; Wals, J; Wils, JA | 1 |
| Asada, M; Egawa-Takata, T; Enomoto, T; Fujita, M; Ito, K; Kimura, T; Kuragaki, C; Miyake, T; Miyatake, T; Morishige, K; Nagamatsu, M; Nakashima, R; Nishio, Y; Nishizaki, T; Ogita, K; Okazawa, M; Tsutsui, T; Ueda, Y; Wakimoto, A; Yamamoto, T; Yamasaki, M; Yoshino, K | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Camporeale, A; Cormio, G; De Mitri, P; Falagario, M; Loizzi, V; Putignano, G; Scardigno, D; Selvaggi, LE | 1 |
| Fu, ZY; Lv, JH; Ma, CY; Wang, T; Yang, DP | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Ghiringhelli, F; Ladoire, S; Pfitzenmeyer, P; Quipourt, V; Rambach, L | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimomura, A; Tamaki, Y; Yasojima, H | 1 |
| Beck, T; Camara, O; du Bois, A; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Höss, C; Kahlert, S; Konecny, GE; Kreienberg, R; Kühn, T; Lebeau, A; Loibl, S; Mehta, KM; Müller, V; Stickeler, E; Untch, M; von Minckwitz, G | 1 |
| Akazawa, K; Ishihara, H; Kim, SJ; Matsushima, T; Nakayama, S; Noguchi, S; Shibayama, M; Shimazu, K; Tamaki, Y; Torikoshi, Y; Tsukamoto, F | 1 |
| Cai, BL; Fu, SM; Guan, SM; Shen, LL; Wu, JZ; Xu, XF; Zhang, J | 1 |
| Bayraktar, S; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Kuerer, HM; Lei, X; Melhem-Bertrandt, A; Meric-Bernstam, F; Sahin, AA; Valero, V | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Breidenbach, M; Duda, V; Eichler, C; Gossmann, A; Harbeck, N; Hoopmann, M; Kates, RE; Ohlinger, R; Thomas, A; Warm, M | 1 |
| Akiyama, F; Ando, M; Aogi, K; Fujiwara, Y; Ino, H; Iwata, H; Kasai, H; Kurosumi, M; Masuda, N; Nakamura, S; Takeuchi, M; Tokuda, Y; Tsuda, H; Yamamoto, N | 1 |
| Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Amano, S; Enomoto, K; Fujisaki, S; Hara, Y; Maeda, T; Nagashima, S; Sakurai, K; Shibata, M; Ueda, Y | 1 |
| Carter, WB; Cox, CE; Gross-King, M; Ismail-Khan, R; Lacevic, M; Minton, SE; Moore, AP; Munster, PN; Xu, P | 1 |
| Bathen, TF; Bofin, A; Cao, MD; Giskeødegård, GF; Gribbestad, IS; Lundgren, S; Lønning, PE; Sitter, B | 1 |
| Kim, SJ; Maruyama, N; Nakamura, Y; Nakayama, T; Naoi, Y; Noguchi, S; Oshima, K; Shimazu, K; Shimomura, A; Tamaki, Y | 1 |
| Kim, SJ; Maruyama, N; Miyake, T; Nakayama, T; Naoi, Y; Noguchi, S; Otani, Y; Shimazu, K; Shimomura, A; Tamaki, Y; Yamamoto, N | 1 |
| Fu, J; Leng, H; Liang, L; Liu, YL; Xing, W; Zhang, HW | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Anker, G; Chrisanthar, R; Knappskog, S; Leirvaag, B; Lundgren, S; Løkkevik, E; Lønning, PE; Miletic, H; Mjaaland, I; Risberg, T; Østenstad, B | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ | 1 |
| Artioli, F; Bagnalasta, M; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; D'Amico, R; Frassoldati, A; Generali, DG; Giardina, G; Guarneri, V; Marini, L; Musolino, A; Orlando, L; Piacentini, F; Ravaioli, A; Sarti, S; Serra, P; Untch, M | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Aavall-Lundquvist, E; Christensen, RD; Eisenhauer, E; Green, J; Havsteen, H; Hirte, H; Izquierdo, MA; Kristensen, GB; Kærn, J; Lindemann, K; Lopez, AB; Ridderheim, M; Stuart, G; Vergote, I; Vrdoljak, E | 1 |
| Bafaloukos, D; Batistatou, A; Bobos, M; Chrisafi, S; Dafni, U; Dimopoulos, MA; Filippidis, T; Fountzilas, G; Gogas, H; Kalogeras, KT; Koletsa, T; Kotoula, V; Koutras, A; Malamou-Mitsi, V; Miliaras, S; Papadopoulos, S; Pectasides, D; Skarlos, DV; Sotiropoulou, M; Televantou, D; Trihia, H | 1 |
| Barutca, S; Meydan, N; Tanriverdi, O | 1 |
| Kim, SJ; Maruyama, N; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimomura, A; Tamaki, Y; Tominaga, N | 1 |
| Climent, F; de Olza, MO; Falo, C; Fernandez-Otega, A; García-Tejedor, A; Germà, JR; Gil-Gil, M; Gumà, A; López-Ojeda, A; Mesia, C; Pérez-Martin, FJ; Pernas, S; Petit, A; Pla, MJ; Urruticoechea, A | 1 |
| Bauerfeind, I; Burghardt, S; Ditsch, N; Hinke, A; Kahlert, S; Konecny, GE; Lenhard, M; Löhrs, B; Loibl, S; Toth, B; Untch, M; Vodermaier, A; Von Koch, F; VON Minckwitz, G | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Abotouk, N; Halim, A | 1 |
| Arnould, T; De Backer, O; Flamant, L; Hayez, A; Michiels, C; Pierre, M; Poumay, Y; Roegiers, E; Sterpin, C | 1 |
| Hao, J; Liu, GY; Wang, DH; Xu, YF; Yu, J; Yuan, BB | 1 |
| Ando-Tanabe, N; Iwamitsu, Y; Kuranami, M; Miyaoka, H; Nakatani, Y; Okazaki, S; Watanabe, M; Yamamoto, K; Yasuda, H | 1 |
| Braun, M; Feller, AM; Fersching, DM; Gabka, CJ; Hamann, U; Heinemann, V; Holdenrieder, S; Nagel, D; Salat, C; Siegele, B; Steinkohl, O; Stoetzer, OJ | 1 |
| Kagara, N; Kim, SJ; Maruyama, N; Morimoto, K; Naoi, Y; Noguchi, S; Oda, N; Shimazu, K; Shimoda, M; Shimomura, A | 1 |
| Ieda, N; Pirovano, C; Siesto, G; Vitobello, D | 1 |
| Mukai, H; Yamaguchi, T | 1 |
| Chavez-Macgregor, M; Chen, H; Do, KA; Gonzalez-Angulo, AM; Hortobagyi, GN; Liu, S; Meric-Bernstam, F; Mills, GB; Sahin, A | 1 |
| Bafaloukos, D; Christodoulou, C; Fountzilas, G; Gogas, H; Kalogeras, KT; Koutras, AK; Kouvatseas, G; Kronenwett, R; Linardou, H; Pectasides, D; Samantas, E; Wirtz, RM; Zagouri, F | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Dong, C; Feng, EF; Gao, CL; He, JC; Luo, CX; Ren, HX; Wang, XN; Yang, RX; Zhuang, L | 1 |
| Conte, C; De Vincenzo, R; Distefano, MG; Ferrandina, G; Petrillo, M; Pietragalla, A; Salutari, V; Scambia, G; Scarciglia, ML | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Bastien, RR; Bernard, PS; Berry, DA; Caballero, R; Carrasco, E; Casas, M; Crespo, C; Davis, C; Ebbert, MT; Ellis, MJ; Furió, V; García, AM; Harris, L; Hudis, C; López-Vega, JM; Martín, M; Munárriz, B; Perou, CM; Pitcher, BN; Prat, A; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Stijleman, IJ; Tuck, DP; Winer, E | 1 |
| Cavaco, TB; Coombes, RC; Gomes, AR; Gong, C; Harada-Shoji, N; Khongkow, M; Khongkow, P; Khoo, US; Koo, CY; Lam, EW; Laohasinnarong, S; Man, EP; Monteiro, LJ; Olmos, Y; Schwer, B; Tsang, JW; Yagüe, E | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Höß, C; Huober, J; Jackisch, C; Khandan, F; Kittel, K; Krabisch, P; Kümmel, S; Loibl, S; Mau, C; Minckwitz, Gv; Nekljudova, V; Rezai, M; Schwedler, K; Tesch, H; Untch, M | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Ayadi, M; Boussen, H; Chraiet, N; Gligorov, J; Krimi, S; Labidi, S; Lagha, A | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Haruta, M; Higuchi, T; Inoue, K; Kaneko, Y; Kasai, F; Kurosumi, M; Miyazaki, M; Ogawa, S; Sato-Otsubo, A; Takada, M; Takei, H; Tozuka, K; Watanabe, J | 1 |
| He, XM; Xiang, H; Yang, HJ; Yu, Y; Zong, XY | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| du Bois, A; Hinke, A; Huober, J; Jackisch, C; Kreienberg, R; Kuhn, W; Kurbacher, C; Lueck, HJ; Moebus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M | 1 |
| Fujita, S; Katagata, N; Matsuzaki, M; Nomizu, T; Saito, M; Sakuma, T; Takenoshita, S; Watanabe, F | 1 |
| Chen, Q; Fan, L; Jiang, J; Qi, X; Wang, S; Yang, X; Zhang, Y | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Blohmer, JU; Eggemann, H; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kittel, K; Kreienberg, R; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schrader, I; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Audhuy, B; Berdah, JF; Buyse, M; Delbaldo, C; Greget, S; Laplaige, P; Mousseau, M; Piedbois, P; Priou, F; Quinaux, E; Serin, D; Teissier, E; Zelek, L | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Boughey, JC; Buzdar, AU; Ellis, MJ; Ewer, MS; Hunt, KK; Leitch, AM; McCall, LM; Meric-Bernstam, F; Royce, M; Suman, VJ; Unzeitig, G | 1 |
| Baba, Y; Kagara, N; Kim, SJ; Kishi, K; Maruyama, N; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y; Tsunashima, R | 1 |
| Abraham, J; Caldas, C; Chan, S; Dean, S; Dunn, J; Earl, HM; Fenwick, N; Gallagher, C; Gounaris, I; Harries, M; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; Iddawela, M; Laing, R; McAdam, K; Provenzano, E; Ritchie, D; Skene, A; Vallier, AL; Wishart, G; Young, J | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Corrado, G; Cutillo, G; Maggioni, A; Mancini, E; Tomaselli, T; Vizza, E; Zanagnolo, V | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Balci, S; Cascione, L; Croce, CM; Fassan, M; Gasparini, P; Guler, G; Huebner, K; Irkkan, C; Lovat, F; Morrison, C; Shapiro, CL | 1 |
| Akcakanat, A; Brewster, AM; Chen, H; Crawford, D; Do, KA; Dryden, MJ; Flores, P; Giordano, SH; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Litton, JK; Liu, S; Meric-Bernstam, F; Mills, GB; Moore, J; Moulder-Thompson, S; Murray, JL; Palla, SL; Pusztai, L; Sahin, A; Symmans, WF; Tarco, E; Valero, V | 1 |
| Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC | 1 |
| Alba, E; Brase, JC; Caballero, R; Calvo, L; Carrasco, E; Casas, M; Crespo, C; Fisch, K; Krappmann, K; Kronenwett, R; Martin, M; Munarriz, B; Petry, C; Rodriguez, CA; Rodriguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Weber, KE | 1 |
| Ando, M; Aogi, K; Fujiwara, Y; Hamano, T; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Ohono, S; Shimizu, S; Sukigara, T; Yamamoto, N; Yamauchi, H | 1 |
| Matsumura, Y | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Arnould, L; Bonnetain, F; Borg, C; Cleau, D; El Gani, M; Fein, F; Fratté, S; Ghiringhelli, F; Jacquin, M; Jary, M; Kim, S; Lamfichekh, N; Lassabe, C; Mathieu, P; Nerich, V; Nguyen, T; Paget-Bailly, S; Valmary-Degano, S | 1 |
| Higaki, K; Kuroi, K; Masuda, N; Matsunami, N; Miyamoto, T; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Takano, T; Toi, M | 1 |
| Bay, JO; Biron, P; Brindel, I; Bui, BN; Caty, A; de Revel, T; Delva, R; Dubot, C; Fizazi, K; Fléchon, A; Gaulet, M; Geoffrois, L; Gligorov, J; Gravis, G; Horn, E; Lotz, JP; Micléa, JM; Provent, S; Roubaud, G; Selle, F; Soares, DG; Temby, I; Wittnebel, S | 1 |
| Cabral, H; Kataoka, K | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Li, GJ; Wang, JJ | 1 |
| Berveiller, P; Mir, O; Selleret, L | 1 |
| Cai, R; Li, Q; Liu, M; Luo, Y; Ma, F; Wang, L; Xu, B; Xu, N | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Costa, D; Queiroz, J; Valente, AJ | 1 |
| Bartsch, R; Deutschmann, C; Felberbauer, FX; Hacker, S; Haslik, W; Kornauth, C; Mader, RM; Thallinger, C | 1 |
| Borani, N; Karalök, MA; Keskin, HL; Köse, MF; Özgül, N; Tulunay, HG; Turan, AT; Üreyen, I | 1 |
| Chavez-MacGregor, M; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Lei, X; Mittendorf, EA; Parinyanitikul, N; Valero, V; Zhang, H | 1 |
| Anan, K; Hayashi, M; Kamata, Y; Maeda, S; Mashino, K; Matsuo, S; Mitsuyama, S; Nishimura, J; Tamura, K; Tanaka, M; Toyoshima, S; Yamaguchi, Y; Yamamoto, Y; Yoshinaga, Y | 1 |
| Amadori, D; Andreis, D; De Giorgi, U; Fabbri, F; Kopf, B; Menna, C; Pietri, E; Rocca, A; Schirone, A | 1 |
| Ardizzoni, A; Barni, S; Bighin, C; Bisagni, G; Boni, C; Bruzzi, P; Cavazzini, G; Cognetti, F; Colantuoni, G; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Forestieri, V; Gamucci, T; Garrone, O; Giuliano, M; Gravina, A; Montemurro, F; Nisticò, C; Papaldo, P; Puglisi, F; Turletti, A; Valle, E | 1 |
| Avery, VM; Lovitt, CJ; Shelper, TB | 1 |
| Kagara, N; Kim, SJ; Maruyama, N; Michishita, S; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y | 1 |
| Li, Y; Shang, YM; Yang, Y; Zheng, H | 1 |
| Bonanno, L; Canova, F; Carli, P; Conte, P; Favaretto, A; Pasello, G; Polo, V; Urso, L; Zago, G | 1 |
| Qiu, ZQ; Qiu, ZR | 1 |
| Bagnardi, V; Barberis, M; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Iorfida, M; Luini, A; Montagna, E; Sangalli, C; Sporchia, A; Veronesi, P; Viale, G | 1 |
| Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Chen, S; Cui, S; Geng, C; Huang, L; Huang, T; Lei, Y; Pang, D; Shao, Z; Song, E; Tang, L; Wang, Y; Xu, B; Yang, H; Yang, W; Zhang, J; Zheng, H | 1 |
| Alfer, J; Burchardi, N; Conrad, B; Decker, T; Denkert, C; Eidtmann, H; Eiermann, W; Hackmann, J; Huober, J; Jackisch, C; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Potenberg, J; Reimer, T; Simon, E; Stickeler, E; Thomssen, C; von Minckwitz, G | 1 |
| Hao, X; Li, C; Su, W; Zhang, J; Zhang, S | 1 |
| Asano, Y; Hirakawa, K; Kashiwagi, S; Kawajiri, H; Kitagawa, S; Noda, S; Ohsawa, M; Onoda, N; Takashima, T | 2 |
| Otsuka, S; Sasaki, Y; Shimada, K; Watanabe, N; Yuasa, T | 1 |
| Accortanzo, V; Adami, F; Bighin, C; Bruzzi, P; Castiglione, F; Cavazzini, G; Conte, P; Danese, S; Del Mastro, L; Durando, A; Garrone, O; Landucci, E; Levaggi, A; Michelotti, A; Miglietta, L; Pastorino, S; Piras, M; Pronzato, P; Scotto, T | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Che, S; Li, J; Ou, Y; Wang, M; Wu, B; Zhao, X; Zhou, C | 1 |
| Bartlett, JM; Boutros, PC; Burnell, M; Chen, BE; D'Costa, A; Levine, MN; Lyttle, N; O'Brien, P; Shepherd, L; Spears, M; Yao, CQ | 1 |
| Cosio, S; Fanucchi, A; Gadducci, A; Lanfredini, N; Menichetti, A; Notarnicola, M | 1 |
| Cárdenas-Rebollo, JM; Colombo, N; Maggioni, A; Minig, L; Zanagnolo, V | 1 |
| Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kodaira, M; Koizumi, F; Komori, O; Nakatochi, M; Okuma, HS; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Boche, D; Bousquet, G; El Bouchtaoui, M; Gourmaud, S; Janin, A; Paquet, C | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Mo, H; Wang, J; Wang, X; Xu, B; Yin, Y; Yuan, P; Zhang, B; Zhang, P; Zheng, S | 1 |
| Ameye, L; Awada, A; Bustin, F; D'Hondt, V; Dal Lago, L; De Azambuja, E; Gombos, A; Ignatiadis, M; Larsimont, D; Lebrun, F; Lemort, M; Maetens, M; Michiels, S; Nogaret, JM; Paesmans, M; Piccart, M; Sotiriou, C; Vanderbeeken, MC; Veys, I; Wilke, C; Zardavas, D | 1 |
| Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Chen, S; Di, GH; Jiang, YZ; Jin, X; Shao, ZM | 1 |
| Aktas, B; Blohmer, JU; Clemens, M; Dan Costa, S; Denkert, C; Engels, K; Gerber, B; Hackmann, J; Hanusch, C; Jackisch, C; Just, M; Kümmel, S; Loibl, S; Nekljudova, V; Paepke, S; Schmatloch, S; Schneeweiss, A; Untch, M; von Minckwitz, G; Warm, M; Wiebringhaus, H | 1 |
| Asano, M; Futamura, M; Ishihara, K; Kawaguchi, Y; Kumazawa, I; Mori, R; Morimitsu, K; Nagao, Y; Nakada, T; Nawa, M; Shimokawa, T; Shiroko, T; Takeuchi, M; Yoshida, K | 1 |
| Bousamra, A; Brewster, AM; Buchholz, TA; Buzdar, AU; Gould, R; Hatzis, C; Hortobagyi, GN; Hunt, K; Liu, M; Moulder, S; Pusztai, L; Ramineni, M; Sinn, B; Symmans, WF; Valero, V; Walls, A; Wei, C; Yang, W; Yu, X; Zhang, Y | 1 |
| Dieras, V; Evans, TJ; Giordano, H; Goble, S; Jaw-Tsai, S; Middleton, MR; Molife, LR; Plummer, R; Roxburgh, P; Spicer, J; Wilson, RH | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M | 1 |
| Chen, J; He, P; Luo, T; Lv, Q; Tan, QW; Tian, TL; Zeng, HL; Zheng, H | 1 |
| Cai, R; Chen, S; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Funakoshi, T; Hirai, I | 1 |
| Anderegg, MCJ; Gisbertz, SS; Hulshof, MCCM; Los, M; Mohammed, NH; Ruurda, JP; van Berge Henegouwen, MI; van der Sluis, PC; van Hillegersberg, R; van Laarhoven, HWM; van Vulpen, M; Wiezer, MJ | 1 |
| Bauerfeind, I; Conrad, B; du Bois, A; Elling, D; Fehm, T; Harbeck, N; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Schneeweiss, A; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Chen, PY; Huang, CY; Lin, FW; Wang, CK; Wei, KC; Yang, HW | 1 |
| Denkert, C; Forstbauer, H; Hoffmann, G; Karn, T; Kohls, A; Köhne, CH; Linn, SC; Loibl, S; Marmé, F; Möbus, VJ; Nekljudova, V; Schem, C; Schmatloch, S; Schouten, PC; Solbach, C; Thomssen, C; van Rossum, AGJ; von Minckwitz, G; Weber, KE | 1 |
| Asher, R; Baron-Hay, S; Gibbs, E; Giuffre, B; Khasraw, M; Mukaro, V; Murphy, C; Tobler, R; West, L | 1 |
| du Bois, A; Harbeck, N; Hinke, A; Huober, J; Jackisch, C; Konecny, GE; Kuhn, W; Kurbacher, C; Lück, HJ; Möbus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kohno, N; Miura, D; Tanino, H | 1 |
| Dai, C; Fu, C; Jia, X; Liu, S; Shen, R; Teng, F; Wu, J; Xu, J | 1 |
| Bergh, J; Brage, SE; Carlsson, L; Einbeigi, Z; Fernö, M; Foukakis, T; Hatschek, T; Linderholm, B; Loman, N; Lorent, J; Lövrot, J; Malmberg, M; Matikas, A; Skoog, L; Suzuki, C; Tobin, N; Zerdes, I | 1 |
| Abu-Khalaf, M; Brandt, DS; Burrello, T; Chagpar, A; DiGiovanna, MP; Foldi, J; Frederick, C; Hatzis, C; Hofstatter, EW; Horowitz, N; Killelea, B; Lannin, D; Mougalian, S; Pusztai, L; Rispoli, L; Sabbath, K; Sanft, T; Silber, A | 1 |
| Akiyama, K; Haku, E; Hayami, R; Kawamoto, H; Kojima, Y; Nishikawa, T; Shimo, A; Tsugawa, K | 1 |
| Biankin, AV; Chantrill, L; Chin, V; Nagrial, A; O'Connor, CA; Scholten, RJ; Sjoquist, K; Yip, D | 1 |
| Alba, E; Álvarez, I; Amir, E; Caballero, R; Calvo, L; Carrasco, E; Casas, M; Crespo, C; Ethier, JL; Gracia Marco, J; Lluch, A; Martin, M; Ocaña, A; Ramos, M; Rodríguez Lescure, A; Rodríguez, CA; Ruíz, A; Ruíz-Borrego, M; Sánchez-Aragó, M; Santaballa, A | 1 |
| Han, D; Li, N; Li, Y; Liu, M; Liu, Z; Ma, J; Peng, R; Sun, J; Wang, H; Wang, J; Zhang, J; Zhang, Y; Zhang, Z | 1 |
| Alan, O; Ercelep, O; Hasanov, R; Kaya, H; Mutis, A; Ones, T; Simsek, ET; Telli, TA; Yumuk, PF | 1 |
| Hazama, Y; Ishida, T; Kurebayashi, J; Matsumoto, K; Matsumoto, R; Moriya, T; Murata, S; Murata, T; Nakai, Y; Nakamura, T; Nomura, T; Shimoya, K; Sugawara, S; Sugihara, M | 1 |
| Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Mazzarello, S; Stober, C; Vandermeer, L | 1 |
| Hayashi, N; Kitani, A; Kuwayama, T; Nakamura, S; Okuyama, H; Sato, T; Takano, T; Tsugawa, K; Yamauchi, H | 1 |
| Chen, S; Ji, R; Li, C; Tang, P; Wang, Q; Wen, J | 1 |
| Boughey, JC; Buzdar, AU; Ellis, MJ; Hunt, KK; Leitch, AM; Meric-Bernstam, F; Royce, ME; Suman, VJ; Unzeitig, GW | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Chang, YJ; Chen, HA; Huang, CY; Huang, MT; Makondi, PT; Wang, JW; Wei, PL | 1 |
| Ashley, D; Baron-Hay, S; Chisanga, D; Collins, I; Khasraw, M; Liao, Y; Lindeman, G; Mukaro, V; Murphy, C; Muscat, A; Patil, S; Shi, W; West, L | 1 |
| Goodwin, A; O'Connell, DL; Wilcken, N; Willson, ML; Zaheed, M | 1 |
| Funakoshi, T; Hirai, I; Ishii, M; Kawakami, Y; Nakamura, Y; Tanese, K | 1 |
| du Bois, A; Harter, P; Hedderich, J; Heilmann, T; Hempel, AM; Hilpert, F; Pfisterer, J; Pujade-Lauraine, E; Saß, S | 1 |
| Blohmer, JU; Burchardi, N; Denkert, C; Engels, K; Fasching, PA; Furlanetto, J; Grischke, EM; Hanusch, C; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Rautenberg, B; Rezai, M; Rhiem, K; Schmitt, WD; Schneeweiss, A; Sinn, BV; Tesch, H; Thomalla, J; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Futsuhara, K; Hata, S; Inoue, K; Kimizuka, K; Kojima, M; Kuroda, T; Nagai, SE; Saito, T; Sakurai, T; Yamada, H; Yamazaki, Y | 1 |
| Kang, Y; Shiraki, E; Tsuyuki, S | 1 |
| Li, M; Lin, Y; Lu, J; Muhetaer, G; Situ, H; Wang, N; Wang, S; Wang, Z; Yang, B; Zhang, F; Zheng, Y | 1 |
| Bao, H; Chen, H; Chen, J; Cong, D; Jia, J; Li, Q; Li, Y; Liu, Z; Luan, X; Lv, Z; Meng, Q; Pei, J; Ren, Z; Sun, F; Tang, H; Wang, L; Yang, Y; Zhao, W; Zhou, X | 1 |
| Bighin, C; Bisagni, G; Bruzzone, M; Ceppi, M; Cognetti, F; Conte, B; de Azambuja, E; De Laurentiis, M; Del Mastro, L; Durando, A; Fabi, A; Garrone, O; Giuliano, M; Lambertini, M; Montemurro, F; Poggio, F; Puglisi, F; Turletti, A; Urracci, Y | 1 |
| Aktan, G; Bergh, J; Cardoso, F; Cortes, J; Denkert, C; Dent, R; Fasching, PA; Foukakis, T; Harbeck, N; Hui, R; Jia, L; Karantza, V; Kümmel, S; McArthur, H; O'Shaughnessy, J; Park, YH; Pusztai, L; Schmid, P; Takahashi, M; Untch, M; Zhao, J | 1 |
| Akabane, H; Fujii, S; Fujisawa, T; Hozumi, Y; Imoto, S; Mizuno, T; Mukai, H; Nishimura, R; Ohsumi, S; Park, Y; Sagara, Y; Takahashi, M; Takashima, T; Toyama, T; Uemura, Y; Yamaguchi, T; Yamashita, S | 1 |
| Fujiwara, Y; Hasegawa, J; Hashimoto, K; Ikeda, K; Kawabata, H; Nishizawa, D; Ozaki, Y; Shimizu, C; Shimomura, A; Shiraishi, S; Takano, T; Tamura, K; Tamura, N; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Fan, Z; He, Y; Li, J; Li, Y; Ouyang, T; Wang, L; Wang, T; Xie, Y | 1 |
| Lambertini, M; Perachino, M; Poggio, F | 1 |
| Alasiri, G; Intuyod, K; Jiramongkol, Y; Ke, HL; Lam, EW; Mahmud, Z; Trakansuebkul, S | 1 |
| Bahkali, AH; Gupta, N; Kumari, RM; Nimesh, S; Sharma, N; Syed, A | 1 |
| Chen, L; Di, GH; Fan, L; Ge, LP; He, M; Jiang, YZ; Jin, X; Liu, GY; Liu, Y; Shao, ZM; Wang, ZH; Wu, J; Yu, KD; Zuo, WJ | 1 |
| Amant, FCH; Beijnen, JH; Bekkers, R; Boere, I; Dorlo, TPC; Drochytek, V; Fruscio, R; Halaska, MJ; Huitema, ADR; Janssen, JM; Ottevanger, P; Painter, RC; Schröder, CP; Van Calsteren, K; Witteveen, PO | 1 |
| Abraham, DT; Andrews, AG; Backianathan, S; Balakrishnan, R; Chacko, RT; Chandramohan, J; Cherian, AJ; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Paul, MJ; Rebekah, G; Sigamani, E; Singh, A; Thumaty, DB | 1 |
| Ge, JY; He, M; Liu, XY; Mo, M; Shao, ZM; Yu, KD | 1 |
| Adriaenssens, E; Angrand, PO; Bidan, N; Chopin, V; Lagadec, C; Le Bourhis, X; Meignan, S; Toillon, RA; Völkel, P; Winter, M | 1 |
| Cui, Y; Fu, S; Leng, Q; Li, Y; Lu, Y; Wang, B; Wu, Z; Xiong, K; Zhao, L; Zhou, P | 1 |
| Ciornei, L; Ciornei, ŞG; Drugociu, D; Roşca, P | 1 |
| Fukuma, Y; Jo, A; Kawano, S; Kishino, E; Koike, Y; Kurebayashi, J; Mikami, T; Nomura, T; Ogata, R; Saito, W; Soda, M; Tanaka, K; Yamamoto, Y | 1 |
| Lukong, KE; Mandapati, A | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kohno, N; Kubota, T; Miura, D; Miyashita, M; Narui, K; Suzuki, M; Tachibana, A; Yamada, A; Yamada, K | 1 |
| Aiso, T; Hasegawa, S; Igarashi, Y; Kimura, Y; Nihei, Y; Ohnishi, K; Ohtake, H; Sai, Y; Satou, T; Takasu, N | 1 |
| Cruz, A; de-Castro-Ríos, A; Lema-Atán, JÁ; Lendoiro, E; López-Rivadulla, M; Paniagua-González, L | 1 |
| Fan, L; Liu, Y; Shao, ZM; Wang, ZH | 1 |
| Asano, Y; Futamura, M; Hosono, Y; Ikawa, A; Ishihara, K; Katagiri, Y; Kawaguchi, Y; Kawajiri, M; Kitazawa, M; Kumazawa, I; Kuno, M; Matsuhasih, N; Mori, R; Morikawa, A; Mushika, Y; Nagao, Y; Nakada, T; Nakakami, A; Niwa, Y; Ogiso, A; Shimokawa, T; Takeuchi, M; Tokumaru, Y | 1 |
| Fan, Y; Kang, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Wang, X; Xu, B; Yuan, P; Yue, J; Zhang, P | 1 |
| Belleville, E; Brucker, SY; Erber, R; Fasching, PA; Fehm, TN; Häberle, L; Hack, CC; Hartkopf, AD; Hartmann, A; Hein, A; Janni, W; Kolberg, HC; Rübner, M; Theuser, AK; Uhrig, S; Untch, M | 1 |
| Chen, R; He, J; Huang, X; Li, X; Ma, L; Shi, W; Wan, X; Wang, J; Wang, L; Wang, Y; Xu, L; Xu, Y; Zha, X; Zhang, W; Zheng, R | 1 |
| Fan, Z; He, Y; Li, J; Ouyang, T; Wang, J; Wang, T; Wang, X | 1 |
| Heibloem, RE; Ilozumba, OUC; Komen, MMC; van den Hurk, CJG | 1 |
| Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ | 1 |
| Amant, FCH; Beijnen, JH; Damoiseaux, D; Dorlo, TPC; Huitema, ADR; Janssen, JM; van Calsteren, K; van Hasselt, JGC | 1 |
| Ikeda, T; Isono, Y; Jinno, H; Maeda, Y; Matsumoto, A; Naruse, S; Sasajima, Y; Sato, A; Yamada, M | 1 |
| Mesén-Porras, S; Molina-Mora, JA; Mora-Rodríguez, R; Quiros, S; Rojas-Céspedes, A; Siles, F; Vega-Baudrit, J | 1 |
43 review(s) available for epirubicin and paclitaxel
| Article | Year |
|---|---|
Control of hepatitis C: a medicinal chemistry perspective.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Design; Enzyme Inhibitors; Hepatitis C; Humans; Molecular Mimicry; Molecular Sequence Data; Nucleoside-Triphosphatase; Nucleosides; Protease Inhibitors; RNA Helicases; RNA, Viral; Structure-Activity Relationship; Viral Nonstructural Proteins | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Fluorouracil; Humans; Ifosfamide; Neoplasm Metastasis; Paclitaxel | 1996 |
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Vinblastine; Vinorelbine | 1996 |
Anthracyclines-paclitaxel combinations in the treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Epirubicin; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
Role of red blood cells in pharmacokinetics of chemotherapeutic agents.
Topics: Administration, Oral; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Doxorubicin; Epirubicin; Erythrocytes; Fluorouracil; Humans; Ifosfamide; Infusions, Parenteral; Mercaptopurine; Methotrexate; Paclitaxel; Platinum Compounds | 1999 |
[Overview of vinorelbine for metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Mitoxantrone; Paclitaxel; Vinblastine; Vinorelbine | 2000 |
Docetaxel and epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2001 |
Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Humans; Paclitaxel; Taxoids | 2001 |
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Italy; Meta-Analysis as Topic; Paclitaxel; Taxoids | 2001 |
New combinations with epirubicin in advanced breast cancer.
Topics: Adult; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Rate; Time Factors | 2001 |
Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Meta-Analysis as Topic; Middle Aged; Paclitaxel; Survival Rate | 2001 |
Paclitaxel: epirubicin in metastatic breast cancer--a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Epirubicin in combination with the taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Epirubicin; Heart Diseases; Humans; Paclitaxel; Taxoids | 2001 |
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Safety; Single-Blind Method; Survival Analysis; Trastuzumab; Treatment Outcome | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Role of epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
Docetaxel-anthracycline combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
[Activity of paclitaxel, epirubicin and carboplatin in patients with advanced or recurrent endometrial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Epirubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Postoperative Care; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Paclitaxel | 2004 |
Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2004 |
[Cardiac prevention: the oncologic point of view].
Topics: Age Factors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Heart; Heart Diseases; Humans; Liposomes; Paclitaxel; Razoxane; Risk Factors; Trastuzumab | 2004 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2011 |
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Mastectomy; Middle Aged; Paclitaxel; Paraneoplastic Syndromes; Ribonucleoproteins; Salvage Therapy; Tamoxifen; Taxoids; Trastuzumab | 2011 |
Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Humans; Ifosfamide; Middle Aged; Mucin-1; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
[Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Paclitaxel; Tamoxifen; Taxoids | 2013 |
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
The drug discovery by nanomedicine and its clinical experience.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cisplatin; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Drug Discovery; Epirubicin; Gas Chromatography-Mass Spectrometry; Humans; Mass Spectrometry; Micelles; Nanomedicine; Nanoparticles; Neoplasms; Neoplasms, Experimental; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polyglutamic Acid; Proteins | 2014 |
Progress of drug-loaded polymeric micelles into clinical studies.
Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Epirubicin; Humans; Irinotecan; Micelles; Neoplasms; Paclitaxel; Platinum Compounds; Polymers | 2014 |
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Nervous System; Neutropenia; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2019 |
[A Case of Stage Ⅳ Triple Negative Breast Cancer(TNBC)in Which S-1 Was Successful against Armor-Like Infiltration of the Chest Wall].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Thoracic Wall; Triple Negative Breast Neoplasms | 2022 |
251 trial(s) available for epirubicin and paclitaxel
| Article | Year |
|---|---|
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fever; Heart Diseases; Humans; Middle Aged; Neutropenia; Paclitaxel | 1996 |
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Tolerance; Epirubicin; Feasibility Studies; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Cyclophosphamide; Epirubicin; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Pleural Neoplasms; Treatment Outcome; Ventricular Function, Left | 1997 |
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Least-Squares Analysis; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 1997 |
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Humans; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quality of Life | 1997 |
Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Middle Aged; Paclitaxel | 1998 |
Paclitaxel plus epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Therapy, Combination; Epirubicin; Female; Humans; Paclitaxel | 1998 |
Phase II study of paclitaxel in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Survival Analysis; Thrombocytopenia; Time Factors | 1998 |
Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Thiotepa | 1998 |
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Failure | 1999 |
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Leukocyte Count; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Recombinant Proteins; Treatment Outcome | 1999 |
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Leukapheresis; Mitoxantrone; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Thiotepa | 1999 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1999 |
Efficacy of epirubicin/paclitaxel combination in mobilizing large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clone Cells; Combined Modality Therapy; Epirubicin; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Middle Aged; Paclitaxel; Prospective Studies; Time Factors; Transplantation, Autologous | 1999 |
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Echocardiography; Epirubicin; Female; Heart Failure; Humans; Life Tables; Middle Aged; Paclitaxel; Risk Factors; Ventricular Function, Left | 1999 |
A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Random Allocation | 1999 |
Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomiz
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Combined Modality Therapy; Drug Synergism; Epirubicin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Statistics, Nonparametric; Treatment Outcome | 1999 |
Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Paclitaxel; Recombinant Proteins | 1999 |
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunohistochemistry; Mastectomy; Mesna; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Protective Agents; Recombinant Proteins; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Codon; Cyclophosphamide; Epirubicin; Exons; Female; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Introns; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Tumor Suppressor Protein p53 | 2000 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Urinary Bladder Neoplasms | 2000 |
Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1999 |
Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Ventricular Function, Left | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Ventricular Fibrillation | 2000 |
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
A multicentre phase II pilot study of epirubicin and Taxol (paclitaxel) in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Heart Function Tests; Humans; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 2000 |
Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2000 |
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2000 |
Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Taxoids | 2000 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Fatigue; Female; Fluorouracil; Glutathione; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2001 |
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Greece; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis | 2001 |
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Epirubicin; Female; Humans; Myocardium; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 2001 |
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Incidence; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Taxoids | 2001 |
Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2001 |
Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Meta-Analysis as Topic; Middle Aged; Paclitaxel; Survival Rate | 2001 |
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Survival Analysis | 2001 |
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cystadenocarcinoma; Disease Progression; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate | 2001 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stomatitis; Taxoids | 2002 |
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Glycerol; Humans; In Vitro Techniques; Infusions, Intravenous; Middle Aged; Paclitaxel | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Treatment Outcome | 2002 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Probability; Risk Assessment; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Sarcoma; Survival Analysis | 2002 |
[Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Docetaxel with epirubicin--investigations on cardiac safety.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular System; Confidence Intervals; Docetaxel; Epirubicin; Female; Follow-Up Studies; Heart Function Tests; Humans; Middle Aged; Paclitaxel; Taxoids | 2003 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Spleen; Splenic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2003 |
Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pilot Projects | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2003 |
The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Hypothermia, Induced; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2003 |
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Recombinant Proteins | 2003 |
Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential follow
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
[Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neurotoxicity Syndromes; Paclitaxel | 2004 |
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute,
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Risk Factors; Ventricular Dysfunction, Left | 2004 |
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left | 2004 |
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2004 |
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Quality of Life | 2004 |
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymph Nodes; Middle Aged; Paclitaxel; Pilot Projects; Risk Factors; Survival Rate; Taxoids | 2004 |
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2005 |
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Autologous; Treatment Outcome | 2005 |
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase I
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2005 |
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2005 |
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Epirubicin; Female; Humans; Leukocyte Count; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Patient Selection; Platelet Count | 2005 |
Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Epirubicin; Feasibility Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome | 2005 |
A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Preoperative Care; Survival Rate | 2005 |
A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Safety; Survival Rate; Treatment Outcome | 2005 |
[Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 2005 |
Preoperative second-line chemotherapy induces objective responses in primary breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2005 |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2005 |
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Risk Assessment; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Sampling Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2005 |
Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Statistics, Nonparametric; Survival Analysis; United Kingdom | 2005 |
Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2006 |
Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Endometrial Neoplasms; Epirubicin; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Treatment Outcome; Uterus | 2007 |
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study G
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Epirubicin; Female; France; Germany; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Prospective Studies; Survival Analysis; Time Factors; Treatment Failure | 2006 |
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Paclitaxel; Prognosis | 2006 |
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Pneumonitis; Radiodermatitis; Razoxane; Recombinant Proteins | 2006 |
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis | 2006 |
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Patient Selection; Proportional Hazards Models; Survival Analysis; Treatment Failure | 2006 |
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gene Expression; Humans; Methotrexate; Middle Aged; Molecular Diagnostic Techniques; Paclitaxel; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Tumor Suppressor Protein p53 | 2006 |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Diarrhea; Drug Administration Schedule; Epirubicin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2006 |
Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Medical Oncology; Outcome Assessment, Health Care; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Research Design | 2006 |
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Echocardiography; Epirubicin; Female; Genes, erbB-2; Humans; Middle Aged; Monitoring, Physiologic; Myoglobin; Paclitaxel; Stroke Volume; Troponin T | 2007 |
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Pilot Projects; Recombinant Proteins; Time Factors | 2007 |
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2007 |
Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Ventricular Function, Left | 2006 |
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Topics: Adipose Tissue; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Double-Blind Method; Epirubicin; Female; Humans; Microdialysis; Paclitaxel | 2007 |
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Ki-67 Antigen; Neoplasm Staging; Paclitaxel; Patient Compliance; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Preoperative Care; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction | 2008 |
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Genes, erbB-1; Humans; Immunohistochemistry; Methotrexate; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis | 2007 |
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Epirubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors | 2008 |
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Endometrial Neoplasms; Epirubicin; Female; Greece; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence | 2008 |
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2008 |
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Fluorouracil; Greece; Humans; Mastectomy; Methotrexate; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Risk Assessment; Treatment Outcome | 2008 |
A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Survival Analysis | 2008 |
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance | 2008 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects | 2008 |
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Research Design; Taxoids; Trastuzumab | 2008 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume; Survival Rate; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2009 |
Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Epoetin Alfa; Erythropoietin; Female; Hematinics; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Recombinant Proteins | 2009 |
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Treatment Outcome | 2009 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Nadroparin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Retrospective Studies; Survival Analysis; Time Factors | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2010 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2010 |
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2010 |
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
Topics: Adult; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel | 2010 |
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multivariate Analysis; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Staging; Paclitaxel; Postmenopause; Premenopause; Survival Analysis | 2010 |
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2010 |
Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dyspnea; Emotions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Quality of Life; Regression Analysis; Sleep Initiation and Maintenance Disorders; Social Behavior; Surveys and Questionnaires; Sweden; Time Factors; Treatment Outcome; Young Adult | 2010 |
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Risk Factors; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Time Factors; Young Adult | 2011 |
A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2010 |
Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Urologic Neoplasms | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Health Status; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Darbepoetin alfa; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Patient Compliance; Preoperative Care; Treatment Outcome; Young Adult | 2011 |
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary brea
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Darbepoetin alfa; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Young Adult | 2011 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeC
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Chemoradiotherapy; Cisplatin; Epirubicin; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Ki-67 Antigen; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Young Adult | 2012 |
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Topics: Antineoplastic Agents; Base Sequence; Breast Neoplasms; Cohort Studies; DNA Primers; Epirubicin; Female; Genes, p53; Genotype; Humans; Mutation; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; Survival Analysis | 2011 |
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Remission Induction; Retrospective Studies | 2011 |
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; CDC2 Protein Kinase; Cyclin-Dependent Kinase 2; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Steroid; Risk Factors; Treatment Outcome | 2012 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Greece; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fertility; Fluorouracil; Follicle Stimulating Hormone; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Inhibins; Menstruation; Neoadjuvant Therapy; Neoplasm Staging; Ovary; Paclitaxel; Tamoxifen; Time Factors; Treatment Outcome; Triptorelin Pamoate | 2012 |
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Epirubicin; Female; Humans; Magnetic Resonance Spectroscopy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Prognosis; Survival Analysis | 2012 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle Proteins; Checkpoint Kinase 2; Cohort Studies; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mitomycin; Mutation; Paclitaxel; Predictive Value of Tests; Promoter Regions, Genetic; Prospective Studies; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Prospective Studies; Quality of Life; Survival Analysis | 2012 |
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Paclitaxel; Treatment Outcome | 2012 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Creatine Kinase, MB Form; Electrocardiography; Epirubicin; Female; Half-Life; Humans; L-Lactate Dehydrogenase; Middle Aged; Myocardium; Paclitaxel | 2012 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Everolimus; Exanthema; Female; Humans; Mastectomy, Segmental; Middle Aged; Mucositis; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2013 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; DNA Topoisomerases, Type II; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Transfusion; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Proportional Hazards Models; Quality of Life; Recombinant Proteins; Risk Assessment; Treatment Outcome | 2013 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Everolimus; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Sirolimus; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Ultrasonography; Young Adult | 2013 |
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Treatment Outcome | 2014 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Puerto Rico; Receptor, ErbB-2; Stroke Volume; Time Factors; Trastuzumab; Treatment Outcome; United States | 2013 |
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2014 |
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2014 |
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2014 |
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Cohort Studies; Drug Monitoring; Epirubicin; Esophageal Neoplasms; Esophagus; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pilot Projects; Severity of Illness Index; Stomach; Stomach Neoplasms; Survival Analysis | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Young Adult | 2014 |
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Thiotepa; Treatment Failure; Young Adult | 2014 |
HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2014 |
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Paclitaxel; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2015 |
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Treatment Outcome; Young Adult | 2015 |
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2015 |
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Epirubicin; Fatigue; Female; Humans; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptors, IgG; Remission Induction; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Routes; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Paclitaxel; Treatment Outcome | 2015 |
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphocytes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutrophils; Paclitaxel; Preoperative Care; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2016 |
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2016 |
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosomal Instability; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Paclitaxel; Prognosis; Taxoids | 2016 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Taxoids; Tissue Array Analysis; Transcriptome; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Recurrence; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2016 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cisplatin; Cyclophosphamide; Diarrhea; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab | 2016 |
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Topics: Aged; Albumins; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2017 |
Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Young Adult | 2017 |
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Prognosis; Survival Rate; Tissue Distribution | 2017 |
Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Young Adult | 2017 |
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Early Diagnosis; Epirubicin; Female; Filgrastim; Germany; Humans; Ibandronic Acid; Middle Aged; Paclitaxel; Polyethylene Glycols; Young Adult | 2017 |
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2017 |
Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
Topics: Adult; Aged; Albumins; Australia; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Sensitivity and Specificity; Trastuzumab | 2018 |
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Risk Factors; Survival Rate | 2018 |
Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Imidazoles; Mastectomy, Segmental; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Receptor, ErbB-2; Zoledronic Acid | 2017 |
Immune gene expression and response to chemotherapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Capecitabine; Epirubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2018 |
Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2018 |
Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Doxorubicin; Endpoint Determination; Epirubicin; Feasibility Studies; Female; Fluorouracil; Guideline Adherence; Humans; Middle Aged; Paclitaxel; Pilot Projects; Random Allocation; Surveys and Questionnaires; Triple Negative Breast Neoplasms | 2018 |
Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Puerto Rico; Receptor, ErbB-2; Risk Factors; Time Factors; Trastuzumab; United States | 2019 |
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Serum Albumin, Human; Trastuzumab; Triple Negative Breast Neoplasms | 2019 |
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Hyperthyroidism; Hypothyroidism; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Placebos; Prospective Studies; Receptor, ErbB-2; Thyroid Gland; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2019 |
Pembrolizumab for Early Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2020 |
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Membrane Proteins; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinorelbine | 2021 |
Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Paclitaxel; Pregnancy; Treatment Outcome | 2021 |
[Neoadjuvant Epirubicin-Cyclophosphamide Therapy followed by Nab-Paclitaxel in Patients with Operable Breast Cancer-A Single-Center Phase Ⅱ Trial].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2022 |
A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2022 |
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2023 |
Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial.
Topics: Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2023 |
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum; Prospective Studies; Quality of Life; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hair; Humans; Hypothermia, Induced; Neoplasms; Paclitaxel; Registries; Scalp | 2023 |
268 other study(ies) available for epirubicin and paclitaxel
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice.
Topics: Adult; Aged; Alkaloids; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Intraductal, Noninfiltrating; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Male; Menogaril; Mice; Mice, Nude; Microtubules; Neoplasm Transplantation; Nogalamycin; Paclitaxel; Pancreatic Neoplasms; Random Allocation; Transplantation, Heterologous | 1987 |
Preoperative taxol induces objective responses in primary breast cancer not responding to FEC treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Resistance, Multiple; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Paclitaxel; Premedication | 1994 |
Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Epirubicin; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Tumor Cells, Cultured | 1994 |
Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Ventricular Function | 1996 |
Extended multidrug resistance in haemopoietic cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hematopoietic Stem Cells; HL-60 Cells; Humans; Leukemia, Myeloid; Paclitaxel; Tumor Cells, Cultured; Vinblastine | 1996 |
Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Paclitaxel | 1997 |
Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Indazoles; Middle Aged; Paclitaxel; Remission Induction; Salvage Therapy; Thymoma; Thymus Neoplasms; Vincristine | 1997 |
Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Platelets; Blood Specimen Collection; Breast Neoplasms; Epirubicin; Female; Filgrastim; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocytes; Middle Aged; Paclitaxel; Recombinant Proteins; Treatment Outcome | 1997 |
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
[Fat accumulation in the gastric submucosa secondary to chemotherapy. A case report documented by computerized tomography].
Topics: Adipose Tissue; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cisplatin; Doxorubicin; Epirubicin; Female; Gastric Mucosa; Humans; Ifosfamide; Lipid Metabolism; Middle Aged; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed | 1997 |
Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Flow Cytometry; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Paclitaxel; Time Factors | 1998 |
Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Epirubicin; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Interactions; Epirubicin; Female; Humans; Mice; Paclitaxel; Taxoids | 1998 |
Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel | 1999 |
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
The pharmacokinetics of epirubicin and docetaxel in combination in rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epirubicin; Male; Metabolic Clearance Rate; Models, Biological; Paclitaxel; Rats; Rats, Sprague-Dawley; Software; Taxoids | 1999 |
Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Drug Synergism; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Paclitaxel; Taxoids | 1999 |
Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Topics: Animals; Anthracyclines; Bridged-Ring Compounds; Chemotherapy, Cancer, Regional Perfusion; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Combinations; Drug Synergism; Epirubicin; Heart; Liver; Male; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids | 2000 |
Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Doxorubicin; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Treatment Outcome | 2000 |
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Paclitaxel-epirubicin in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects | 1999 |
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Regression Analysis; Sensitivity and Specificity; Survival Analysis; Tumor Cells, Cultured | 2000 |
Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Adjuvant chemotherapy for early breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Paclitaxel | 2000 |
Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Survival; Chlorambucil; Cisplatin; Daunorubicin; Drug Resistance, Multiple; Epirubicin; Genistein; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.
Topics: Adaptor Proteins, Signal Transducing; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Bone Marrow; Carrier Proteins; Caspase 3; Caspase 8; Caspase 9; Caspases; Child; Epirubicin; Fas Ligand Protein; fas Receptor; Fas-Associated Death Domain Protein; Humans; Immunoblotting; Lymphoma, B-Cell; Membrane Glycoproteins; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transfection; Tumor Cells, Cultured | 2001 |
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Liver Neoplasms; Middle Aged; Paclitaxel; Soft Tissue Neoplasms; Thiotepa; Treatment Outcome | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Risk | 2001 |
Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Volume; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukocyte Count; Male; Middle Aged; Paclitaxel; Time Factors | 2001 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cell Survival; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Flow Cytometry; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunomagnetic Separation; Keratins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stem Cells; Taxoids; Time Factors; Tumor Cells, Cultured | 2001 |
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Radiation-Protective Agents; Radiation-Sensitizing Agents | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
The integration of anthracyclines in the treatment of advanced ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Epirubicin; Female; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
[Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Combined Modality Therapy; Cryosurgery; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Immunotherapy; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Picibanil; Taxoids | 2001 |
[Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Failure | 2001 |
Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capillaries; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelium, Vascular; Epirubicin; Humans; Irinotecan; Paclitaxel; Phenotype; Skin; Vascular Endothelial Growth Factor A | 2001 |
Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
Docetaxel induced durable response in advanced extramammary Paget's disease: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Paclitaxel; Paget Disease, Extramammary; Radiography; Scrotum; Skin Neoplasms; Taxoids; Vincristine | 2002 |
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2002 |
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Drug Monitoring; Epirubicin; Female; Fluorouracil; Humans; Mammography; Mastectomy; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Paclitaxel; Physical Examination; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Collagen; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Gels; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids | 2002 |
Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Eruptions; Epirubicin; Erythema; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paresthesia; Skin; Taxoids | 2002 |
[Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2002 |
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disulfiram; Docetaxel; Drug Interactions; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epirubicin; Female; Humans; Paclitaxel; Razoxane; Taxoids; Tretinoin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Docetaxel; Epirubicin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2002 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Central Nervous System Neoplasms; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2002 |
[Chemotherapy protocol with taxol increase survival by 31 percent].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2002 |
Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Prospective Studies; Remission Induction; Treatment Outcome | 2003 |
Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cyclophosphamide; Docetaxel; Enzyme Inhibitors; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, p53; Genes, Tumor Suppressor; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Paclitaxel; Preoperative Care; Receptors, Steroid; Taxoids; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2003 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation.
Topics: Antigens, CD; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Filgrastim; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Immunologic Memory; Lymphocyte Depletion; Paclitaxel; Recombinant Proteins; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation, Autologous | 2003 |
Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography.
Topics: Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Epirubicin; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Mammography; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Radionuclide Imaging; Technetium Tc 99m Sestamibi; Treatment Outcome | 2003 |
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Lineage; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Epirubicin; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Paclitaxel; Th2 Cells | 2003 |
[Cylindroma of the trachea, a rate tumor with unusual evolution].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Adenoid Cystic; Cisplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Radiography, Thoracic; Radiotherapy Dosage; Taxoids; Tracheal Neoplasms; Treatment Outcome | 2003 |
Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Contrast Media; Cyclophosphamide; Epirubicin; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction | 2003 |
[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cryosurgery; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Injections, Intralesional; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Taxoids | 2003 |
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Rate; Treatment Outcome | 2004 |
The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prognosis | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2004 |
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Up-Regulation | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
[Taxol based chemotherapy in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Remission Induction; Stomach Neoplasms | 2004 |
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Estradiol; Female; Fluorouracil; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Collagen; Culture Media; Drug Screening Assays, Antitumor; Epirubicin; Fluorouracil; Gels; Humans; Liver Neoplasms; Paclitaxel; Tissue Embedding | 2004 |
Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Epithelial Cells; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2005 |
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Topics: Biomarkers; Breast Neoplasms; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Microtubules; Paclitaxel; RNA, Messenger; tau Proteins | 2005 |
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Membrane; Cytoplasm; Drug Resistance, Neoplasm; Endothelium; Epirubicin; Epithelium; Female; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Receptor, ErbB-2; Treatment Outcome; Tubulin; Vascular Endothelial Growth Factor Receptor-1 | 2005 |
[Feasibility of breast conservation surgery after neoadjuvant chemotherapy for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Adenosquamous carcinoma of the uterine cervix--adjuvant chemotherapeutic treatment with paclitaxel and carboplatin; a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Epirubicin; Ethanol; Fatal Outcome; Female; Gynecologic Surgical Procedures; Humans; Injections, Intralesional; Liver Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Sclerosing Solutions; Sclerotherapy; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
Long-term prevention of skeletal complications by pamidronate in a patient with bone metastasis from endometrial carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Endometrial Neoplasms; Epirubicin; Female; Humans; Paclitaxel; Pamidronate | 2006 |
[A case of locally advanced breast cancer successfully treated with FEC (100) followed by weekly paclitaxel].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Mastectomy, Modified Radical; Paclitaxel | 2005 |
[The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Neoadjuvant Therapy; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone | 2005 |
Lasting remission following multimodal treatment in a patient with metastatic breast cancer.
Topics: Adult; Antibodies; Antigens, Neoplasm; Breast Neoplasms; CD3 Complex; Cell Adhesion Molecules; Combined Modality Therapy; Epirubicin; Epithelial Cell Adhesion Molecule; Female; Humans; Leukapheresis; Liver Neoplasms; Paclitaxel; Remission Induction; Thiotepa; Treatment Outcome | 2005 |
Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2005 |
[Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2005 |
Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies | 2006 |
Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2006 |
A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2006 |
Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoplasm Staging; Paclitaxel; Physical Examination; Retrospective Studies | 2006 |
Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2006 |
Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.
Topics: Adult; Aged; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Calcium-Binding Proteins; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Epithelial Cell Adhesion Molecule; Female; Fluorouracil; Follow-Up Studies; Humans; Keratins; Membrane Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; Presenilin-2; Prognosis; Receptor, ErbB-2; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Risk Factors; RNA Precursors; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thiotepa; Treatment Outcome | 2006 |
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Radical; Megestrol Acetate; Middle Aged; Paclitaxel; Palliative Care; Skin Neoplasms | 2006 |
Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
Topics: Aged; Antineoplastic Agents; Cytosol; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorenes; Heart; Humans; Hydantoins; Hydrogen Peroxide; Male; Middle Aged; Myocardium; Paclitaxel; Reactive Oxygen Species; Taxoids | 2007 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Heart Block; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2007 |
Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Salvage Therapy; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Evaluation of the effect of paclitaxel, epirubicin and tamoxifen by cell kinetics parameters in estrogen-receptor-positive ehrlich ascites tumor (eat) cells growing in vitro.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Division; Cell Survival; Epirubicin; Kinetics; Male; Mice; Mice, Inbred BALB C; Mitotic Index; Paclitaxel; Polyploidy; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured | 2007 |
[Surgery for advanced breast cancer from the viewpoint of medical oncologist].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2007 |
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Texas; Trastuzumab; Treatment Outcome | 2007 |
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukapheresis; Lung Neoplasms; Middle Aged; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins | 2007 |
Chemo-conization in early cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Conization; Epirubicin; Female; Fertility; Humans; Ifosfamide; Paclitaxel; Uterine Cervical Neoplasms | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neutropenia; Paclitaxel; Postoperative Period; Retrospective Studies; Taxoids | 2007 |
[A case of left breast cancer resulting in complete response by primary systemic therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Paclitaxel; Treatment Outcome | 2007 |
Histological features of breast cancer, highly sensitive to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2007 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast Neoplasms; CD40 Antigens; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mastectomy; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; RNA, Messenger; Signal Transduction; Transcription, Genetic; Trastuzumab; Treatment Outcome; Up-Regulation | 2007 |
Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Epirubicin; Female; Flow Cytometry; Hyaluronan Receptors; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Tumor Cells, Cultured | 2008 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Paclitaxel; Positron-Emission Tomography; Treatment Outcome | 2008 |
S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Calcium-Binding Proteins; Cell Proliferation; Epirubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2008 |
[Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Time Factors | 2008 |
[Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Humans; Japan; Lymphatic Metastasis; Middle Aged; Paclitaxel; Time Factors | 2008 |
Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Conization; Epirubicin; Female; Humans; Hysterectomy; Ifosfamide; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms; Young Adult | 2008 |
XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; DNA-Binding Proteins; Epirubicin; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Glutathione S-Transferase pi; Humans; Interferon-gamma; Methylenetetrahydrofolate Dehydrogenase (NADP); Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Uterine Cervical Neoplasms; X-ray Repair Cross Complementing Protein 1 | 2008 |
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Remission Induction; Retrospective Studies; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.
Topics: Analysis of Variance; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Statistics, Nonparametric; Taxoids; Vault Ribonucleoprotein Particles | 2008 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Preoperative Care; Treatment Outcome | 2009 |
[Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Time Factors; Treatment Outcome | 2009 |
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2009 |
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Humans; Japan; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2009 |
Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Epirubicin; Humans; Hydrogen-Ion Concentration; Paclitaxel; Photochemotherapy; Urinary Bladder Neoplasms; Urocanic Acid | 2009 |
The stage of offspring of female rats after treatment with cytostatics of various groups.
Topics: Animals; Carboplatin; Cisplatin; Cytostatic Agents; Drug Administration Schedule; Epirubicin; Etoposide; Female; Male; Paclitaxel; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Time Factors | 2008 |
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antibiotics, Antineoplastic; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD24 Antigen; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Hyaluronan Receptors; Isoenzymes; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplastic Stem Cells; Paclitaxel; Retinal Dehydrogenase | 2009 |
Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Female; Genes, erbB-2; Humans; Ki-67 Antigen; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone | 2009 |
[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Survival Rate | 2009 |
Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen | 2009 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Treatment Outcome; Triazoles; Tumor Burden | 2010 |
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Retrospective Studies | 2010 |
Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2009 |
[A case of aggressive primary squamous cell carcinoma of the breast refractory to preoperative neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Epirubicin; Fatal Outcome; Female; Fluorouracil; Humans; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Vinblastine; Vinorelbine | 2009 |
Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Flow Cytometry; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2009 |
[A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Drug Combinations; Epirubicin; Female; Fluorouracil; Humans; Oxonic Acid; Paclitaxel; Pentoxifylline; Quality of Life; Tegafur; Treatment Outcome | 2009 |
Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Paclitaxel; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2010 |
Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Trastuzumab; Treatment Outcome | 2010 |
[Clinical experience in the treatment of ovarian carcinoma and the role of the nurse during the hemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Nurse-Patient Relations; Ovarian Neoplasms; Paclitaxel; Young Adult | 2009 |
Optimal chemotherapy for high-risk early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2010 |
Simultaneous determination of anthracyclines and taxanes in human serum using online sample extraction coupled to high performance liquid chromatography with UV detection.
Topics: Anthracyclines; Antineoplastic Agents; Blood Proteins; Calibration; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Humans; Paclitaxel; Sensitivity and Specificity; Taxoids | 2010 |
[A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Quality of Life; Tomography, X-Ray Computed | 2010 |
Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2011 |
Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model.
Topics: Animals; Antineoplastic Agents; Carboplatin; Cytarabine; Doxorubicin; Epirubicin; Female; Fetal Blood; Gestational Age; Injections, Intravenous; Maternal-Fetal Exchange; Mice; Mice, Inbred C57BL; Models, Animal; Paclitaxel; Placenta; Pregnancy; Vinblastine | 2011 |
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bleomycin; Carboplatin; Case-Control Studies; Chromatography, High Pressure Liquid; Dacarbazine; Doxorubicin; Epirubicin; Female; Humans; Models, Animal; Paclitaxel; Papio; Pregnancy; Spectrophotometry, Atomic; Vinblastine | 2010 |
Advanced inoperable type B3 thymoma: monitoring of a novel therapeutic approach with radio-chemotherapy and sorafenib by FDG-PET and CT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Image Processing, Computer-Assisted; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiography; Radionuclide Imaging; Taxoids; Thymoma; Thymus Neoplasms; Treatment Outcome | 2010 |
[Practice and consideration on neoadjuvant therapy for early breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Burden | 2010 |
Optimizing dose-dense regimens for early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Erythropoietin; Female; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Analysis | 2010 |
Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Therapy, Computer-Assisted; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2010 |
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Letrozole; Middle Aged; Nitriles; Paclitaxel; Triazoles; Tryptophan | 2010 |
Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Sensitivity and Specificity | 2011 |
Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cluster Analysis; Cyclophosphamide; Epirubicin; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Mutation; Paclitaxel; Tumor Suppressor Protein p53 | 2011 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromones; Epirubicin; Female; Humans; Morpholines; NF-kappa B; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrrolidines; Signal Transduction; Thiocarbamates; Tissue Inhibitor of Metalloproteinase-1 | 2011 |
Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2011 |
Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Female; Fluorouracil; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Oligonucleotide Array Sequence Analysis; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Predictive Value of Tests; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Ultrasonography, Mammary | 2011 |
Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bleomycin; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Fluorescent Antibody Technique, Indirect; Fluorouracil; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Salivary Gland Neoplasms | 2011 |
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2012 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Imaging, Three-Dimensional; Middle Aged; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Ultrasonography, Mammary | 2011 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
[Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hormone Replacement Therapy; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Letrozole; Middle Aged; Nitriles; Paclitaxel; Time Factors; Triazoles | 2011 |
14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Topics: 14-3-3 Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Methylation; Drug Resistance, Neoplasm; Epirubicin; Exonucleases; Exoribonucleases; Female; Fluorouracil; Humans; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Promoter Regions, Genetic; Retrospective Studies; Sequence Analysis, DNA; Treatment Outcome; Tumor Suppressor Protein p53 | 2012 |
GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA Methylation; Drug Resistance, Microbial; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Neoadjuvant Therapy; Paclitaxel; Promoter Regions, Genetic; Receptors, Estrogen | 2012 |
[Invasive ductal carcinoma and chronic lymphocytic leukemia: a unique case of collision tumor in breast].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel | 2011 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vinblastine; Vinorelbine | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; Keratin-5; Methotrexate; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Young Adult | 2012 |
Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Electrocardiography; Epirubicin; Female; Heart; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Radiotherapy; Receptor, ErbB-2; Retrospective Studies; Time; Trastuzumab | 2012 |
Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Breast Neoplasms; Cyclophosphamide; Epirubicin; ErbB Receptors; Female; Fluorouracil; GATA3 Transcription Factor; Hepatocyte Nuclear Factor 3-alpha; Humans; Ki-67 Antigen; Middle Aged; Mucin-1; Neoadjuvant Therapy; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Sequence Analysis, DNA; Treatment Outcome | 2012 |
TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Female; Gene Amplification; Gene Dosage; Gene Expression; Humans; Neoadjuvant Therapy; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Keratinocytes; Liver Neoplasms; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome | 2012 |
[Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Nocodazole; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyploidy; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Vincristine | 2012 |
Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cognition; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neuropsychological Tests; Paclitaxel; Prognosis; Stress, Psychological; Taxoids | 2014 |
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; HMGB1 Protein; Humans; Mucin-1; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor for Advanced Glycation End Products; Taxoids; Trastuzumab | 2013 |
Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Forkhead Transcription Factors; Humans; Interleukin-17; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; T-Lymphocytes, Regulatory | 2012 |
Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Laparoscopy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Robotics; Safety; Treatment Outcome; Uterine Cervical Neoplasms; Vagina | 2013 |
Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Monitoring; Epirubicin; Female; Humans; Japan; Ki-67 Antigen; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2012 |
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Protein Array Analysis; Proteomics; Taxoids | 2013 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms | 2013 |
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Clinical Trials, Phase III as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
Topics: Acetylation; Animals; Biomarkers, Tumor; Breast Neoplasms; Cell Death; Cell Nucleus; Cell Survival; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Epirubicin; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Immunohistochemistry; Kaplan-Meier Estimate; MCF-7 Cells; Mice; Paclitaxel; Proportional Hazards Models; Sirtuins | 2013 |
Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemot
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosome Aberrations; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Survival Rate; Trastuzumab | 2013 |
[A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Remission Induction | 2013 |
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Genes, MHC Class II; Humans; Middle Aged; Models, Biological; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Prognosis; Retrospective Studies; Transcriptome; Treatment Outcome | 2014 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: a multi-institution study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pelvis; Retrospective Studies; Robotics; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Keratin-5; Keratin-6; Methotrexate; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Risk Assessment; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
Topics: Adult; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Multicenter Studies as Topic; Outcome Assessment, Health Care; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Reproducibility of Results; Retrospective Studies | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Relationship between RFC gene expression and intracellular drug concentration in methotrexate-resistant osteosarcoma cells.
Topics: Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Gene Expression; Humans; Ifosfamide; Methotrexate; Osteocytes; Paclitaxel; Reduced Folate Carrier Protein; RNA, Messenger; Tritium | 2014 |
Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics.
Topics: Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; ROC Curve; Treatment Outcome | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Plasmid DNA nanogels as photoresponsive materials for multifunctional bio-applications.
Topics: Biocompatible Materials; Cells, Cultured; DNA; Doxorubicin; Drug Delivery Systems; Epirubicin; Fibroblasts; Humans; Nanogels; Paclitaxel; Photolysis; Plasmids; Polyamines; Polyethylene Glycols; Polyethyleneimine | 2015 |
Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Body Mass Index; Cisplatin; Device Removal; Dioxoles; Epirubicin; Equipment Failure; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Risk Factors; Surgical Flaps; Tetrahydroisoquinolines; Therapeutic Irrigation; Trabectedin; Vascular Access Devices; Young Adult | 2015 |
Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy -a retrospective evaluation. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Young Adult | 2014 |
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2015 |
[Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
Evaluation of chemotherapeutics in a three-dimensional breast cancer model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Epirubicin; Female; Humans; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Cyclophosphamide; Decision Support Techniques; Epirubicin; Estrogen Receptor alpha; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2015 |
Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Case-Control Studies; Cyclooxygenase 2; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine | 2015 |
[Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Liposomes; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2015 |
Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Stroke Volume; Time Factors; Trastuzumab; Ventricular Function, Left | 2015 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
Role of the Intravoxel Incoherent Motion Diffusion Weighted Imaging in the Pre-treatment Prediction and Early Response Monitoring to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests | 2016 |
Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cohort Studies; Cytoreduction Surgical Procedures; Epirubicin; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2016 |
Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Longitudinal Studies; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Robotic Surgical Procedures; Taxoids; Uterine Cervical Neoplasms | 2016 |
Effect of anti-cancer drugs on microglia in patient-derived breast cancer xenografted mouse models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Mice; Mice, Nude; Microglia; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphocyte Count; Middle Aged; Paclitaxel; Platelet Count | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
Topics: Adult; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Gene Expression; Humans; Ki-67 Antigen; Logistic Models; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Nomograms; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; ROC Curve; Sentinel Lymph Node Biopsy; Trastuzumab; Tumor Burden | 2016 |
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Phenotype; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Rate; Time Factors; Trastuzumab; Tumor Burden | 2017 |
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism | 2017 |
Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Care; Preoperative Care; Treatment Outcome | 2017 |
Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Administration Schedule; Epirubicin; Genital Neoplasms, Male; Groin; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Paclitaxel; Paget Disease, Extramammary; Scrotum; Skin Neoplasms; Treatment Outcome | 2017 |
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Perioperative Care; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2017 |
Rapid
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Drug Therapy, Combination; Epirubicin; Gliosarcoma; Humans; Hydrogels; Infusion Pumps, Implantable; Magnetic Resonance Imaging; Mice; Neoplasm, Residual; Paclitaxel; Secondary Prevention; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured | 2017 |
Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Computational Biology; Databases, Genetic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; RNA, Long Noncoding | 2018 |
Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Transcriptome | 2018 |
Subtypes of MDSCs in mechanisms and prognosis of gastric cancer and are inhibited by epirubicin and paclitaxel.
Topics: Aged; Animals; Apoptosis; Epirubicin; Female; Flow Cytometry; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Middle Aged; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Paclitaxel; Prognosis; Stomach Neoplasms | 2018 |
A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis | 2019 |
[A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease Progression; Epirubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic | 2018 |
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Databases, Genetic; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; RNA, Long Noncoding; RNA, Messenger; ROC Curve; Transcriptome; Triple Negative Breast Neoplasms | 2018 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Membrane Glycoproteins; Osteosarcoma; Paclitaxel | 2019 |
Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Genital Neoplasms, Male; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Paget Disease, Extramammary; Prognosis; Progression-Free Survival; Retrospective Studies; Scrotum; Severity of Illness Index; Thrombocytopenia; Vulvar Neoplasms | 2019 |
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Drug Administration Schedule; Epirubicin; Female; Humans; Medication Adherence; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Topotecan; Tumor Burden; Young Adult | 2019 |
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Silicates; Survival Rate; Titanium; Triple Negative Breast Neoplasms | 2020 |
[Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients].
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2019 |
XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line; Cell Survival; Chemokine CXCL1; Drug Resistance, Neoplasm; Drug Synergism; Drugs, Chinese Herbal; Epirubicin; Female; Gene Expression Regulation; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Oviposition; Paclitaxel; Zebrafish | 2019 |
Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Epirubicin; Estrone; Female; Humans; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Paclitaxel; Particle Size; Polyethylene Glycols; Receptors, Estrogen; Tissue Distribution | 2020 |
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Middle Aged; NAV1.7 Voltage-Gated Sodium Channel; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate | 2020 |
Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2021 |
Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Ovary; Paclitaxel; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Epirubicin; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Indoles; MAP Kinase Signaling System; MCF-7 Cells; Paclitaxel; Protein Serine-Threonine Kinases; Signal Transduction | 2020 |
Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Carriers; Drug Liberation; Epirubicin; Humans; Hydrogen-Ion Concentration; Kinetics; Lung Neoplasms; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer | 2020 |
Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Infertility; Neoplasms; Paclitaxel; Pregnancy; Pregnant Women; Taxoids | 2021 |
Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
Topics: Adult; Anemia; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2021 |
Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms; Vimentin; Zebrafish | 2021 |
Injectable hydrogel loaded with paclitaxel and epirubicin to prevent postoperative recurrence and metastasis of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Epirubicin; Female; Humans; Hydrogels; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel | 2021 |
Ovarian response to P4-PGF-FSH treatment in Suffolk sheep and P4-PGF-PMSG synchronization in cross-bred ewes, for IVD and ET protocol.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cattle; Embryo Transfer; Epirubicin; Female; Follicle Stimulating Hormone; Male; Ovary; Paclitaxel; Prostaglandins F; Sheep; Sheep, Domestic | 2022 |
Triple negative breast cancer: approved treatment options and their mechanisms of action.
Topics: Docetaxel; Doxorubicin; Epirubicin; Humans; Paclitaxel; Triple Negative Breast Neoplasms; United States | 2023 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
LC-MS-MS Determination of Cytostatic Drugs on Surfaces and in Urine to Assess Occupational Exposure.
Topics: Chromatography, Liquid; Cyclophosphamide; Cytostatic Agents; Epirubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Occupational Exposure; Paclitaxel; Tandem Mass Spectrometry; Vinorelbine | 2023 |
Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lipopolysaccharides; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2023 |
Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Mitoxantrone; Paclitaxel; Vemurafenib | 2023 |
Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.
Topics: Antineoplastic Agents; Child; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Models, Biological; Neoplasms; Paclitaxel; Pregnancy | 2023 |
Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Mastectomy; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2023 |
Sphingolipid-Based Synergistic Interactions to Enhance Chemosensitivity in Lung Cancer Cells.
Topics: Ceramides; Cisplatin; Epirubicin; Humans; Kinetics; Lung Neoplasms; Paclitaxel; Sphingolipids | 2023 |